HPV testing on self-collected  cervico-vaginal material: a new way of woman-friendly cervical screening by Gok, M.
1 
 
 
 
 
 
 
 
 
 
HPV TESTING ON SELF-COLLECTED CERVICO-VAGINAL  
 
MATERIAL:  
 
A NEW WAY OF WOMAN-FRIENDLY CERVICAL SCREENING 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Murat Gök 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The work described in this thesis was performed at the Department of Pathology (head Prof.dr. C.J.L.M. Meijer), VU 
University Medical Center, Amsterdam, The Netherlands.  
Financial support for this work was provided by Delphi Bioscience B.V. 
 
 
 
Cover designed by  H.C.J. Wesker 
   Graphics and Images.nl 
 
 
 
 
 
ISBN: 978-94-6182-105-8 
© copyright by Murat Gök, 2012  
All rights reserved. No part of this publication may by reproduced or transmitted in any form or by any means, 
electronic, mechanical, photocopy, recording or otherwise, without prior permission from the holder of the copyright. 
3 
 
VRIJE UNIVERSITEIT 
 
 
 
 
HPV testing on self-collected cervico-vaginal material: a new way of 
woman-friendly cervical screening 
 
 
 
 
 
 
ACADEMISCH PROEFSCHRIFT 
 
ter verkrijging van de graad Doctor aan 
de Vrije Universiteit Amsterdam, 
op gezag van de rector magnificus 
prof.dr. L.M. Bouter, 
in het openbaar te verdedigen 
ten overstaan van de promotiecommissie 
van de Faculteit der Geneeskunde 
op dinsdag 15 mei 2012 om 13.45 uur 
in de aula van de universiteit, 
De Boelelaan 1105 
 
 
 
 
door 
 
 
Murat Gök 
 
 
geboren te Zaandam 
4 
 
promotoren:  prof.dr. C.J.L.M. Meijer 
   prof.dr. P.J.F. Snijders 
copromotoren: dr. F.J. van Kemenade 
   dr. D.A.M. Heideman 
5 
 
List of Abbreviations 
 
 
HPV  Human Papillomavirus 
CIN  Cervical Intraepithelial Neoplasia 
PAP  Papanicolau 
SIL  Squamous Intraepithelial Lesion 
HSIL  High-grade Squamous Intraepithelial Lesion 
LSIL  Low-grade Squamous Intraepithelial Lesion 
HC2  Hybrid Capture 2 
PCR  Polymerase Chain Reaction 
PALGA Pathologisch Anatomisch Landelijk Geautomatiseerd Archief 
RR  Relative risk 
GP  General practitioner 
LLETZ  Large Loop Excision of the Transformation Zone 
6 
 
Contents 
 
 
 
Chapter 1 Introduction            
 
Chapter 2 Cytology history preceding cervical cancer diagnosis:     
a regional analysis of 286 cases       
 
Chapter 3 HPV testing on self-collected cervico-vaginal lavage  
specimens is an effective screening method for non- 
attendees of cervical screening: results from the  
PROHTECT cohort study        
 
Chapter 4 Experience with high-risk human papillomavirus testing on  
vaginal brush-based self-samples of non-attendees of the  
cervical screening program        
 
Chapter 5 Offering self-sampling for human papillomavirus testing to      
non-attendees of the cervical screening programme:  
Characteristics of the responders 
 
Chapter 6 HPV16 and increased risk of recurrence after treatment for CIN   
 
Chapter 7 Discussion & Summary        
 
Chapter 8 Nederlandse samenvatting        
 
List of publications         
 
Acknowledgement         
 
Curriculum Vitae         
 
  
 
 
 
7 
 
8 
 
9 
 
 
 
 
 
 
 
 
Chapter 1 
 
Introduction 
 
 
 
1.1 Cancer of the uterine cervix 
1.1.1 Epidemiology of cervical cancer 
1.1.2  Anatomy of the uterine cervix 
1.1.3 Precursor lesions and cervical cancer 
 
1.2 Human papillomavirus (HPV) 
1.2.1 Causative agent of cervical cancer 
1.2.2 HPV genome and taxonomy 
1.2.3 Prevalence of HPV infections 
1.2.4 Viral life cycle and transforming HPV infections 
1.2.5 Concept of cervical carcinogenesis 
 
1.3 New ways to prevent cervical carcinoma 
1.3.1 Organised screening programme of The Netherlands 
1.3.2 Primary prevention by prophylactic HPV vaccination 
1.3.3 Secondary prevention by HPV DNA testing  
 1.3.4 Self-sampling 
1.3.5 Triage of hrHPV-positive women  
 
 
1.4 Aim and outline of this thesis 
10 
 
 1.1 Cancer of the uterine cervix 
  
1.1.1 Epidemiology of cervical cancer 
 
Cervical cancer is the second most common female cancer in the world. Worldwide, an 
estimated 437,000 new cases of invasive cervical cancer are diagnosed yearly, of which more 
than 80% occur in developing countries.(1) More than 233,000 women die from cervical cancer 
each year. Thus, worldwide cervical cancer is a major cause of death, accounting for 6-10% of 
all cancer related deaths in women.(2) The age-standardized incidence rates in developed 
countries are less than 14 per 100,000, compared to up to 43 per 100,000 in developing 
countries. This difference in incidence may partly be explained by introduction of cervical cancer 
screening programmes in the 60s and 70s of the previous century in developed countries.(3-5) 
The Netherlands is among the countries with one of the lowest incidence of (7.9 new 
cases per 100,000 women in the year 2007) and almost the lowest mortality from cancer of the 
uterine cervix (1.7 per 100,000 women).(6) Yearly, approximately 630 cases of cervical cancer 
are diagnosed, while the yearly number of death is about 225 deaths.(7) The risk for a Dutch 
woman to be diagnosed with or die from cervical cancer before she reaches the age of 75 is 
0.46% and 0.13%, respectively.(8) From 1988 (11.8 per 100,000 women yearly) to 2000 (8.2 per 
100,000 women years) an incidence reduction of 2.7% was observed, mainly caused by a 
decrease in the incidence of squamous cell carcinoma (SCC).(9) Besides a natural decline due 
to better sexual hygiene after the second world war, the decrease of SCC could for a large part 
be explained by introduction of organized cervical screening.(10)  
Squamous cell carcinoma (SCC) is the most common histotype of cervical cancer (80%-
85%%). The second most common type is cervical adenocarcinoma (AdCa), which constitutes 
approximately 10%-15% of cervical cancers. The remaining 5% are rare histotypes, including 
small cell carcinoma.(11)  
 The prognosis depends on the patient's age and general health, the stage and type of 
the cervical cancer. 
 
1.1.2 Anatomy of the uterine cervix 
 
The cervix is the entrance of the uterus and is divided into the vaginal portio (ectocervix) 
and the endocervix. The ectocervix and the vagina are covered by a stratified nonkeratinizing 
squamous epithelium continuous with the vaginal vault. The endocervical canal is lined by tall 
columnar cells. Somewhere on the cervix the two cell types, squamous cells and columnar cells, 
meet at a place microscopically called the squamo-columnar junction (SCJ). The position of the 
junction is variable because of both the cervical anatomy and age-related hormonal influences. 
From puberty onwards sqamous metaplasia replaces the columnar epithelium at the SCJ. The 
area between the original SCJ and the current SCJ is called transformation zone (TZ). The TZ is 
thought to be most susceptible to high-risk human papillomavirus infection and subsequent 
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(HPV)-mediated transformation of cervical cells. This is typically the area in which abnormal 
growth or dysplasia develops.  
 
1.1.3  Precursor lesions and cervical cancer 
   
Cervical SCC typically develops in the mucosa of the TZ via premalignant precursor 
lesions, so called cervical intraepithelial neoplasia (CIN). These histologically recognizable foci 
of abnormal growth or dysplasia can be classified on the basis of progressive atypia of the 
epithelial cell lining. The classification system has 3 levels; CIN 1 (mild dysplasia), CIN2 
(moderate dysplasia), and CIN3 (severe dysplasia). CIN1 means that the lower 1/3 of the total 
thickness of the squamous epithelium shows atypia (mild dysplasia). For CIN2 the lower 2/3 of 
the total thickness of the epithelium (moderate dysplasia), and for CIN3 the complete epithelial 
layer shows atypia (severe dysplasia and carcinoma in situ). 
This three-tiered classification has recently been simplified to a two-tiered classification 
on the basis of a two-tiered decision management (observation vs. surgical treatment). The CIN 
I has been renamed into low-grade squamous intraepithelial lesion (LSIL), and CIN II/III into 
high-grade squamous intraepithelial lesion (HSIL). LSILs have a low progression rate to invasive 
carcinoma, and in clinical practice are therefore not treated, . Instead surveillance takes place of 
women with LSIL. HSILs are recognized as immediate precursors of cervical SCC, and therefore 
surgically treated,e.g. by large loop excision of the transformation zone (LLETZ) in order to 
prevent cervical cancer.  
Cervical AdCa arises within glands located in the endocervix. The different stages of 
precursor lesions of cervical AdCa, i.e cervical intraepithelial glandular neoplasias (CIGN) grade 
1 and 2 are histologically poorly defined and therefore their natural history not completely 
understood. The best defined precursor lesion is CIGN 3 or adenocarcinoma in situ (ACIS), 
which requires treatment. As is the case for CIN2/3 and SCC, high-risk HPV infection is 
necessary for development of ACIS and AdCa (see chapter 1.2).(12) 
 
 
1.2 Human papillomavirus (HPV) 
 
1.2.1 Causative agent of cervical cancer 
 
The first suggestion that cervical cancer was a sexually transmitted disease was done by 
Rigoni-Stern in the 19th century.(13) However, it was not until mid-70s of the 20th century that the 
role of HPV in the development of cervical carcinoma was discovered by Nobel price-winner 
Harald zur Hausen.(14) Many studies have supported the causative role of an infection with 
high-risk HPV (hrHPV) in the development of high-grade premalignant cervical lesions(15), and 
cervical cancer(16-18) The hrHPV prevalence in cervical carcinomas is >99.7%.(19) The World 
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Health Organization accepted an infection with hrHPV as the primary cause of cervical cancer in 
2005.(20)  
 
 
1.2.2 HPV genome and taxonomy  
 
HPVs are double-stranded DNA viruses of approximately 8,000 base pairs wrapped into a 45-55 
nm sized spherical protein shell (capsid). HPVs belong to the family of Papillomaviridae,(21;22) 
which comprise papillomavirus (PV) types isolated from humans, non-human mammals, birds 
and reptiles. HPVs are strictly epitheliotrophic, and can be subdivided into cutaneous 
(predominantly infects the skin) and mucosal types based on their preferential site of infection. 
The latter types do infect the mucosa of the anogenital, respiratory and/or upper digestive 
tract.(23;24) This thesis will focus on the mucosal types.  
The HPV DNA contains two coding regions, i.e., an early region encoding proteins 
necessary for viral replication (E1, E2, E4, E5, E6, E7) and a late region encoding the major and 
minor viral capsid proteins (L1 and L2), and one non-coding long control region, the latter of 
which contains regulatory elements (see Figure 1).  
 
Figure 1: Genomic organization of HPV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To classify a new HPV type, subtype, or intratype variant, the homology in the genomic 
sequence of L1, E6 and E7 open reading frames is taken into account. Sequence variation of 
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>10%, 2-10%, and <2%, classifies a new type, subtype, or intratype variant, respectively. To 
date, more than 120 HPV types have been identified.(22;25;26). The HPV types can be 
categorized into species, and these species into genera (see Figure 2). 
 
The majority of HPV types, so-called low risk types, are associated with benign wart-like 
lesions. A subset of HPVs may eventually cause malignant transformation of the infected 
epithelium, and these types are therefore designated as high-risk (hr), or oncogenic types. The 
International Agency for Research on Cancer (IARC) has categorized HPV types according to 
their carcinogenicity to humans into different classes(27). The oncogenic potential differs 
between hrHPV types. The types found most frequently in cervical cancer (HPV-16, 18, 31, 33, 
35, 45, 52, 58) and four types less constantly found (HPV-39, 51, 56, 59) are categorized into in 
Group 1 (Table 1). Among these, HPV16, and -18 confer the highest risk of high-grade CIN 
lesions and cervical cancer (>CIN2).(28-31) HPV-68 was classified as ―probably carcinogenic to 
humans‖ (Group 2A) with limited evidence in humans but strong mechanistic evidence. The 
remaining types of HPV in the high-risk alpha species were classified as ―possibly carcinogenic‖ 
(Group 2B). Finally, HPV-6 and HPV-11, which belong to the alpha-10 species, were not 
classifiable as carcinogenic for humans (Group 3) on the basis of inadequate epidemiological 
evidence and absence of carcinogenic potential in mechanistic studies. Nonetheless, some 
studies suggest HPV6 and -11 as possibly carcinogenic to human beings, which warrants further 
investigation.(32)  
 
1.2.3 Prevalence of HPV infections  
 
Genital HPV infections are very common. The HPV prevalence depends on geographic 
area and age. The HPV prevalence is highest among women between the age of 16 and 25 
years (approximately 20%). The highest prevalence rates have been detected in Africa and 
South America, while the prevalence rates are the lowest in Europe and Asia.(33) Worldwide, 
the HPV prevalence in women with normal cytology at any moment in time is approximately 
10%. This indicates that HPV is one of the most common sexually transmitted infections.(34) It is 
estimated that about 80% of sexually active individuals encounter an HPV infection during their 
life, most of which pass unnoticed.(35) Moreover, 80% of all hrHPV infections will not result in 
lesions and are referred to as transient infections. The remaining 20% results in morphological 
changes, read as CIN1, CIN2 or CIN3 lesions by pathologists. Often these lesions will regress 
following clearance of the virus, but is highest in CIN1 and lowest in CIN3 lesions. Thus, genital 
HPV infections are very common, but only a few HPV-infected individuals (~1-3%) ultimately 
show progression to invasive cancer.(36)  
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Figure 2: Phylogenetic tree of Papilloma viruses  
 
 
 
Adapted from Bernard et al, Virology 2010 
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Table 1: Classification of HPV types according to oncogenic potential  
 
Group 
Alpha HPV types 
α7, α 9, α10 
Comments 
1 Alpha 9: 16 Most potent HPV type, known to cause cancer at several sites 
1 
Alpha 5: 51 
Alpha 6: 56 
Alpha 7: 18, 39, 
45, 59 
Alpha 9: 31, 33, 
35, 52, 58 
Sufficient evidence for cervical cancer 
2A Alpha 7: 68 
Limited evidence in humans but strong mechanistic evidence for 
cervical cancer 
2B 
Alpha 5: 26, 82 
Alpha 6: 53, 66 
Alpha 7: 70, 
Alpha 9: 67 
Limited evidence in humans for cervical cancer 
2B Alpha 7: 85, 97  
Classified by phylogenetic analogy to HPV types with sufficient or 
limited evidence in humans 
3 Alpha 10: 6, 11 
Most commonly associated with benign lesions such as genital 
warts and mild dysplasia of the cervix 
 
 
  
1.2.4  Viral life cycle and transforming HPV infections 
 
HPV infections normally have a tight connection to the differentiation process of the host 
cell. The viral genome is maintained as an episome in the basal cells, viral DNA replication 
occurs in the suprabasal layers, encapsidation takes place in the upper layers of the host 
epithelium, and finally viruses are shed when the superficial epithelial cells die. Besides the viral 
proteins E1 and E2, which are essential for viral replication, the virus relies entirely on the host 
cell DNA replication machinery for viral DNA synthesis. Viral E5, E6 and E7 proteins are needed 
to create conditions that allow viral replication in differentiated non-dividing epithelial host cells, 
in which the DNA replication machinery is normally not activated. This form of HPV infection in 
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which new viral particles are formed is referred to as a productive infection. Such infections may 
give rise to mild or moderate histomorphological abnormalities (CIN1 and CIN2), but usually do 
not result in development of >CIN3. 
On the other hand, transforming infections are associated with high-grade CIN lesions 
and cervical cancer. These infections are characterized by excess expression of the viral E6 and 
E7 oncogenes in the proliferating cell compartment of the epithelium and abortion of the normal 
viral life cycle. Interactions of the viral oncoproteins with cellular tumor suppressor proteins, 
particularly E6 with p53 and E7 with pRb in these proliferating cells provide a basis for genomic 
instability. The accumulation of (epi)genetic alterations trigger malignant transformation (see 
Figure 3).(37;38)  
It is thought that transforming infections develop through progression of a minority of 
productive HPV infections by a mechanism not fully understood. Genomic loss, integration of the 
virus in the cellular genome and Methylation of E2 binding sites are thought to play a role in 
progression to a transforming infection. 
 
Figure 3: progression model of cervical carcinoma 
 
 
1.2.5 Concept of cervical carcinogenesis 
 
As a result of a transforming hrHPV infection, CIN3 lesions may develop relatively fast, i.e. 
within 3 years.(39;40) Up to 50% of CIN3 lesions can progress to cancer if left untreated, a 
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process which may take 10-30 years.(3;41) Thus, although hrHPV infections are necessary to 
cause cervical cancer, it is far from sufficient. Additional genetic aberrations, including the 
accumulation of (epi)genetic alterations, is required for a precursor lesion to become invasive.  
 
1.3 Ways to prevent cervical carcinoma 
 
1.3.1  Organised cervical screening programme  
 
The fact that cervical cancer develops via premalignant precursor lesions which can be 
treated effectively, offers possibilities for screening to prevent cervical cancer development. In 
The Netherlands, cervical cancer screening using the Pap smear was introduced in the 
beginning of 1970‘s. The target was women between the age of 35-55 years with a smear taken 
every 3 years.  
It was clear that this programme failed to meet standards set by the WHO. The system 
became nationwide only in 1988 and the programme mainly reached younger women, as the 
age target was set on 35-55 years of age. Furthermore, in 1990 the invitational reach of 
organised cervical screening programme was approximately 85%.(7) Approximately 69% of 
invited women did participate the screening programme. In addition, many cytology tests were 
read as abnormal (~14%), resulting in many repeat tests. Also the timely compliance rate with 
recommendations for a repeat smear was less than 50%. 
 In order to amend the lack of full coverage, the underscreening of invited higher age 
groups, the overscreening of lower age groups and to limit the number of repeat tests, the 
secretary of health council ordered a revision of the current programme in 1991. However, the 
screening programme still showed too much lack and still did not meet standards set by WHO. 
In 1996, the Dutch cervical screening organisation was revisited again. To avoid 
overscreening and to allow extension of the programme to older age stata all women aged 
between 30 and 60 years (instead of 35-55 years) were invited every 5 years. Thus, the number 
of invitations per life time did not change.(42)  
As a result, the 5-year coverage in the age range 30-64 years increased from 69% in 
1994 to 77% in 2003. The percentage of smears resulting in a recommendation for a repeat 
smear decreased from 10 to 2. The percentage of timely compliance with recommendations for 
a repeat smear increased from 47 to 86, while that of smears with an immediate referral 
recommendation remained the same. Also, the percentage of women receiving an invitation for 
screening rose from 85% to 98%.(7) Another important change in the restructuring was 
implementation of a new follow-up algorithm combined with a more consistent classification of 
the cytological smear results (CISOE-A classification). Briefly, the CISOE-A classification 
interprets smears using a rating system including information on specimen composition, 
inflammatory characteristics, and adequacy of the smear. The letters C (composition), I 
(inflammation), S (squamous), O (other and endometrium), and E (endocervical glandular 
epithelium) are used to indicate the composition and morphology of the smears. As a result the 
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percentage of women with borderline or mild dyskaryosis (BMD) decreased from 11.3% in 1990 
to 2.6% in 2000 (p < 0.001)(43). The CISOE-A interpretations can be easily ―translated‖ into the 
Bethesda classification (see Table 2; adapted from Bulk et al, 2004(43)).  
Moreover, in case of BMD, women received two additional smears at 6 and 18 months: if 
any of these repeat smears was read as outside normal limits (BMD or worse) women were to 
be referred for colposcopy directed biopsy (so called indirect referral). Women with cytology 
results worse than mild dyskaryosis were referred immediately to a gynaecologist (so called 
direct referral based on one smear result). Finally, reimbursement for general practitioners (GPs) 
was, according to the algorithm, limited to programme smears only, giving a strong disincentive 
to spontaneous or opportunistic smears. The last major change in the organised screening 
programme was recently introduced when the number of founded screening organisations was 
reduced from 12 to 5, and these were given full governance in order to save costs and maintain 
quality.  
 
Table 2: CISOE-A classification 
S O E Pap Description Bethesda 2001  
0 0 0 0 Inadequate Unsatisfactory for evaluation  
1 1 1–2 1 Normal Negative for intraepithelial lesion or malignancy  
1 2 1–2 1 Normal Atrophy, negative for intraepithelial lesion or 
malignancy 
 
2–3 3 3 2 Borderline dyskaryosis ASC-US/ASC-H AGC 
4 4 4 3a1 Mild dyskaryosis ASC-H/LSIL AGC favour neoplastic 
5 5 5 3a2 Moderate dyskaryosis HSIL AGC favour neoplastic 
6 6 6 3b Severe dyskaryosis HSIL AGC favour neoplastic 
7 − 7 4 Carcinoma in situ HSIL AIS 
8–9 7–8 9 5 Carcinoma Squamous cell carcinoma Adenocarcinoma 
AGC, atypical glandular cells; AIS, endocervical adenocarcinoma in situ; ASC-H, atypical squamous cells cannot exclude HSIL; 
ASC-US, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; HSIL, high grade 
squamous intraepithelial lesion, encompassing CIN2–3; LSIL, low grade squamous intraepithelial lesion, encompassing CIN1. 
 
Despite the improved changes, the effects of screening programmes on carcinoma 
incidence (and mortality) are still being debated. Incidence of and mortality from SCC started to 
decrease already in the fifties before the organised screening programme was introduced.(10) 
The decrease may partly be caused by natural declining, probably caused by improved sexual 
hygiene. Moreover it is difficult to prove (without randomised controlled trials) that the 
introduction of screening has contributed to the decrease in the incidence SCC in the 
Netherlands.(9) In addition, modelling studies have suggested that the Dutch screening 
programme would reduce the risk of dying from cervical cancer by 75%, under the assumption 
that all women would adhere to the programme and comply with all 7 invitations. Yet, this aim 
seems increasingly unlikely.(44)  
However a recent British publication described that without cervical screening an epidemic of 
cervical cancer would have occurred in the UK.(3)  
19 
 
As mentioned above, the incidence of cervical cancer in The Netherlands decreased 
between the year 1988 and 2000.(9) However, the incidence of cervical cancer cases does not 
seem to have reached its bottom.(45) The main cause is the limited compliance of women to 
participate, reflected by either complying with screening at less than the recommended 
frequency or non-participation at all (non-responders; see below). Yet, other causes cannot be 
excluded, such as an increase in carcinoma incidence owing to a changed lifestyle.(3;45) In 
addition, failures in the process (smear taking, smear handling, screening and/or interpretation of 
abnormal cells, reporting failures), cause failures in diagnosis ,treatment and follow-up 
monitoring.(46)  
An additional complication is the presumed shift in histotype from SCC to AdCa of the 
uterine cervix. Although the original modelling was done for SCC, the incidence of AdCa either 
remained the same or even increased in some countries.(47-49) For patients with AdCa the 
relative risk (RR) of death is 1.6 times higher compared to patients with SCC (95% CI 1.2 – 
2.1).(9) Cytology seems to be more efficient in detecting (pre-)malignant stages of SCC than 
those of AdCa.(9)  
Every year, approximately 800,000 are invited, but ~528,000 women (~66%) do attend to 
the organised screening programme in the Netherlands (see Figure 5. Source: RIVM; 
www.rivm.nl/bevolkingsonderzoeknaarbaarmoederhalskanker/onderwerpen).  
A considerable number of women are not screened at all.(50) In addition, approximately 
65% of women participates the screening programme (see Figure 4), 12% of women have 
opportunistic screening or are screened by indication. Thus, nearly 23 % of the invited women 
do not undergo any screening. Several studies have portrayed the screening histories of women 
with histologically confirmed cervical cancer.(51-53) The conclusion of these studies was that 
lack of an adequate cervical screening history (i.e. not being screened) was the major risk 
factor, but also misreading of smears, inconsistent or delayed follow-up after an abnormal smear 
or a not representative smear were important reasons for failure to detect (precursor lesions of) 
cervical cancer.  
Previous study showed that in the period 2000-2003, the number of cervical cancer was 
~650 per year in The Netherlands. The mortality from cervical cancer was ~230 women per 
year.(7) More than half of these women (~55%) was not screened in the previous round prior to 
the histologically confirmed diagnosis. Possible reasons for the non-participating may be the 
inconvenience of having a smear taken, the time required, the estimated risk a woman 
considers herself to have and the discomfort.(54) Increasing screening participation, therefore, 
seems essential to decrease the number of cervical cancer even more.(55;56) 
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Figure 4: attendance rate of the organised screening programme 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source : RIVM 
 
 
 
1.3.2 Primary prevention by prophylactic HPV vaccination 
 
On the basis of the insight that cervical cancer is caused by hrHPV types, two new 
directions have emerged for the prevention of cervical cancer: primary prevention by 
prophylactic vaccination against high-risk types HPV-16 and HPV-18, which are worldwide 
responsible for approximately 70% of cervical cancers(57) and secondary prevention by cervical 
screening with HPV DNA testing. 
 The currently available prophylactic HPV vaccines are based on virus like particles 
(VLPs) of HPV16 and HPV18 composed of HPV L1 proteins VLP‘s develop spontaneously by 
folding of the isolated HPV 16 and 18 L1 proteins. The currently available vaccines are the 
quadrivalent vaccine Gardasil® (MSD), which besides HPV16 and HPV18 also contains VLP‘s 
of non-oncogenic types HPV6 and HPV11 and the bivalent vaccine Cervarix®; (GSK) vaccines. 
A VLP is geometrically and antigenically almost identical to the native virion. Thus, VLPs 
resemble the actual virus morphologically but cannot induce infection as these do not contain 
viral DNA. Once introduced intramuscularly, VLP vaccines generate high levels of systemic anti-
HPV L1 immunoglobulin G (IgG) antibodies. There is now substantial evidence that the serum-
neutralising IgG antibodies induced by these HPV-VLP vaccines and produced by plasmacells in 
bone marrow and lymph nodes reach the anogenital epithelial surface through diffusion. They 
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prevent attachment of the HPV particle to the epithelium and as such an HPV infection. They 
provide protection against persistent infection of epithelial cells with HPV types represented in 
the vaccine and against incident and persistent CIN2+ lesions caused by the vaccine HPV type. 
Protection is in principle type-specific, but cross-reactivity against HPV45, partially against 
HPV31 and HPV33 has been proven(58) and may occur against other phylogenetically related 
HPV types because they share cross-neutralisation epitopes.(59) Neither one of the vaccines is 
effective in persons that are already infected with HPV, and consequently these vaccines have 
no therapeutic effect. In public prevention programmes, HPV vaccination should therefore be 
confined to preadolescent girls and/or boys that are not yet sexually active and considered 
immunologically naive for HPV. Modelling has shown that vaccination of girls is probably 
sufficient to attain sufficient immunity in a population (herd immunity). 
Indeed, many countries have started vaccination programmes, primarily targeting 
preadolescent girls.(60) In the Netherlands, the HPV vaccine has been incorporated into the 
national vaccination programme and started with vaccination of girls aged 12 years in 2010 
(http://www.rivm.nl). 
 
 
1.3.2 Secondary prevention by HPV DNA testing 
 
The effect of implementing HPV testing has been investigated in several population-
based screening trials, the results of which indicate that HPV DNA testing detects 50% more 
high-grade lesions as compared to cytology.(61) HPV DNA testing detects clinically relevant 
lesions at an earlier stage. The result is that women with a negative HPV tests result have a 
markedly decreased risk of developing high-grade CIN lesions(62-74) and cervical cancer(75) in 
the next screening round (three or five years later, compared to women with a cytologically 
negative smear, permitting less frequent screening.  
The HPV test used in these trials are the hybrid capture 2 (HC2) test and the GP5+-6+-
PCR-EIA assay, which are considered clinically validated for screening purposes.(76;77) The 
hrHPV HC2 is a signal amplification method in a liquid-phase format and uses a mixture of full-
length RNA probes representing 13 HPV types (i.e. HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59 and 68) to hybridize to HPV DNA in heat-alkaline-denatured samples. RNA/DNA hybrids 
are detected by peroxidase-labeled antibodies and visualized by electro-chemiluminescence 
(ECL).(78) The GP5+/6+PCR-EIA test is a PCR-based assay, amplifying L1 DNA of a broad 
spectrum of HPV types. The read-out system involves an enzyme immunoassay (EIA) staining 
procedure using oligoprobe cocktails representing high-risk and ⁄ or low-risk HPV types.(79) 
Presently a commercial version is available.(80) 
Finally, many more different HPV tests are available. However, it was already recognised in 
2003 that it is of utmost importance to define criteria that should be fulfilled by an HPV test 
before the implementation of such a test in a population-based cervical cancer screening 
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programmes(81) and such guidelines recently have been made by an international 
consortium.(76) 
 
 
1.3.4 Self-sampling 
  
As mentioned in paragraph 1.3.1, the compliance rate of women attending regular 
screening programme needs to be increased, given a substantial non-attendance rate of ~23% 
and the fact that more than half of the diagnosed cervical carcinomas is found in this group. 
Several methods may lead to improvement of participation by invited women in organised 
screening programmes. Hermens et al. have shown that women are more willing to attend when 
invitations are sent by their general practitioner instead of the municipality.(82) Another 
alternative to influence the effectiveness of the screening programme is computerization and, to 
a lesser degree, more intensive support to practices and delegation of many clinical tasks to the 
practice assistant.(83)  
Most importantly, simplifying the procedure for women by offering a self-sampling device 
for collecting cervico-vaginal material may positively affect the participation rate.(54;84-87)This 
method potentially can lower the threshold for participation that normally is not reached because 
of embarrassment, language difficulties, fear or lack of time during daytime for working women, 
and/or culture differences. Epidemiological studies in which participants were asked for 
collection preference have shown that women prefer self- collection over physician-
collection.(88-92) Time and place of sampling, privacy and ease of sampling have been 
mentioned as advantages of self-sampling. Even 40% of older women not participating in 
organised screening preferred performing self-sampling.(93) This could lead to a reduction of 
cervical cancer incidence by about 16% among postmenopausal women, if self-sampling would 
be offered.(94) Thus, there is a basis for HPV testing on self-sampled of vaginal- or cervico-
vaginal material in cervical cancer screening. 
Self-collected vaginal samples are not suited for accurate cytological assessment, 
because insufficient intact cervical cells are represented in these specimens and cytological 
preparations may be of poor quality.(95), resulting in too low sensitivity for cervical 
lesionsMoreover, liquid-based cytology (LBC) preparations of self-sampled specimens showed a 
poor concordance with cytology on conventional cervical smears taken by a physician and 
revealed much lower sensitivities for high-grade cervical disease.(96) Thus, cytology is not an 
option for self-sampled cervico-vaginal specimens.  
Conversely, sufficient evidence has been collected that self-sampling is as sensitive as 
physician-obtained sampling to detect hrHPV.(90;96-99) Moreover, hrHPV testing on self-
sampled material has been demonstrated to be at least as sensitive for detection of >CIN2 as 
cytology on cervical sampled material with endocervical brush obtained by the 
physician.(54;96;100-102) In fact, highly concordant results can even be obtained between 
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hrHPV testing on self-sampled cervico-vaginal material and physician-sampled specimens at the 
level of >CIN2.(91;103-105)  
All these data open possibilities to offer self-sampling for hrHPV testing to non-attendees of the 
cervical screening program as a method to increase compliance. Indeed, in a pilot study we 
found that offering self-sampling for hrHPV DNA testing to the non-attendees in the cervical 
screening programme is a feasible method.(85) This study showed that ~30% of the non-
attendees did respond by submitting a self-collected sample. This pilot study therefore indicates 
feasibility of offering hrHPV self-sampling to non-attendees, which warrant further investigations 
on effectiveness.  
 
1.3.5 Triage of hrHPV positive women 
 
The consequence of primary hrHPV testing for cervical screening, however, is the 4-6% lower 
specificity of this assay, as compared to cytology, for high-grade cervical lesions. The number of 
false-positive results, i.e. positive hrHPV results without presence of high-grade precursor 
lesions may lead to unnecessary follow-up and a considerable increase in colposcopies. In order 
to keep follow-up procedures and associated costs within acceptable limits additional triage 
steps of hrHPV positive women are necessary. Cytology, HPV genotyping, viral load analysis, 
p16 INK4A staining, E6/E7 expression analysis, and promoter methylation analysis of tumor 
suppressor genes have been proposed as triage tools.(106-108) At present cytology has been 
shown the best triage tool to identify the women who are in need of immediate colposcopy. 
However, because the 2 years-risk of >CIN3 of hrHPV positive women without cytological 
abnormalities is still above the level of acceptance (a CIN3+ risk of 42.2% (95% confidence 
interval (CI): 36.4-48.2), whereas the hrHPV-positive women with normal cytology had a much 
lower risk of 5.22% (95% CI: 3.72-7.91) with 1% for CIN3+ according to the Dutch screening 
guidelines a repeat cytology test after 6 or 12 months may be used to further decrease the 
number of colposcopy).(109) In future screening, it is likely that the role of cytology becomes 
more and more limited. A promising alternative to cytology is p16INK4A immunostaining.(110) 
Also promoter methylation analysis of tumor suppressor genes like CADM1 and MAL have 
yielded promising results but their value needs further confirmation in larger studies.(111;112) 
Such molecular markers could be of particular value when considering self-sampled cervico-
vaginal samples for which cytology is not an effective option (see next paragraph). When proven 
successful promoter methylation markers will open the way for fully non-morphological 
screening.  
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1.4 Aim and outline of this thesis 
  
Despite well-organized cervical screening, still approximately 628 cases of cervical cancer are 
diagnosed in the Netherlands each year. It is important to elucidate why screening may not be 
fully effective and to investigate ways to improve the cervical cancer screening programme.  
 
We wondered what the influence of screening history was in women who acquired cervical 
cancer. Special attention was paid to attendancy. Therefore in Chapter 2 we analyzed women 
with cervical cancer between 2005–2007 for cytology history preceding carcinoma, hierarchically 
arranging cytology history (if present) into three groups: ‗screened (between 1 and <6 years prior 
to diagnosis)‘, ‗work-up (<1 year prior to diagnosis)‘ and ‗underscreened‘, (>6 yrs prior to 
diagnosis). For screen- and work-up smears we analyzed timeliness. FIGO-stage were 
measured in relation to cytology history. Women with cervical cancer are underscreened and 
have poor timeliness in case of abnormal cytology. Being un- or underscreened correlates 
significantly with higher cervical cancer stages, especially in older women (aged >49 years; 
p<0.001). We concluded that Improvement of attendancy is needed to meet the standards of 
quality for screening programmes. 
 
Enhancing participation is important in achieving optimal protection from screening 
programmes. We therefore assessed the effect of offering self-sampling for hrHPV testing to 
non-responders of the regular cervical screening programme in the PROHTECT (PRotection by 
Offering HPV TEsting on Cervico-vaginal specimens Trial) studies. Main outcome measures 
included the compliance rate, the detection rate of CIN2+, and the concordance of HPV-test 
results between the self-sampled material and material sampled by the general practitioner.  
 
Chapter 3 describes the findings of the PROHTECT 1 trial (n=27,163), performed 
between December 2006 – March 2007 within the setting of the organised screening 
programme. We compared the attendance rate of women who received a lavage self-sampling 
device (intervention group) to that of women who received a re-invitation for conventional 
cytology (recall control group). Furthermore, the yield of >CIN2/>CIN3 in self-sampling 
responders was assessed. We showed that offering hrHPV testing on self-sampled vaginal 
material with a lavage self-sampling device to non-attendees significantly increases the 
attendance to the regular screening program, shows very good concordance with HPV test 
results on physician-taken scrapes in women with high-grade CIN, and proofed to be an 
effective way to detect high-grade CIN. The study demonstrated that offering self-sampling by 
sending a device for collecting cervico-vaginal specimens for high-risk HPV testing to women 
who did not attend regular screening is a feasible and effective method of increasing coverage in 
a screening programme. The response rate and the yield of high-grade lesions supported 
implementation of this method for women, not responding to an invitation for regular screening. 
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Chapter 4 describes the findings of the PROHTECT 2 trial (n=25,822), performed 
between December 2007 – March 2008 within the setting of the organised screening 
programme. In this trial, we evaluated the use of a brush-based vaginal self-sampling device in 
non-attendees of the cervical screening program for response rate, compliance to follow-up, 
concordance of HPV test results between physician-taken cervical scrapes and vaginal self-
samples and CIN2+/CIN3+ yield. The same outcome parameters were assessed as in 
PROHTECT-1. Also this study demonstrated that offering self-sampling by sending a brush 
based device for collecting cervico-vaginal specimens for high-risk HPV testing to women who 
did not attend regular screening is a feasible and effective method of increasing coverage in a 
screening programme. However although the percentage of HPV positive women was lower 
than that of women using a lavage based device, the yield of CIN2, /CIN3 and cervical cancer 
was similar. The total yield of DNA sampled by the brush was 3x lower than that of the lavage 
based device. 
 
In Chapter 5 we compared the yield of CIN2+, CIN3+ and cervical cancer in the self-
sampling responder women from the pooled PROHTECT studies (~30% of the non-responder 
women) who originally did not react to an invitation for regular cervical screening. Moreover we 
analysed the yield of CIN2+, CIN3+ and CxCa in the HPV responding group of the non-
responders in relation to ethnicity and age of the women. 
..  
 
Women, who did not react upon an invitation for regular screening (non-responder 
women) respond better to sending a device for self-collection of cervico-vaginal material for HPV 
testing (~30%) than to a reïnvitation for making a smear by a physician (11%). The relative risks 
for CIN2+ (1.6 (95%CI 1.4-1.9%) and CIN3+ (95%CI 1.5-2.1%) was significantly higher in the 
HPV responders in the non-responder group than in the regular responders of the cervical 
screening programme. From the non-reponder women,who react upon self-sampling devices 
those with the poorest screening history proved to have the highest risk for CIN2+, CIN3 and 
cervical carcinomas. Interestingly, independent of age and ethnicity, the self-sampling approach 
targets better the non-responder women who have never been screened and have the highest 
risk for (precursor lesions of) cervical cancer than women who were underscreened.  
 
Women treated for CIN2+ are better followed by HPV testing in combination with 
cytology than by sole cytology. Moreover it is well known that women with HPV 16 infection have 
the highest risk for cervical cancer.(12;29;31) and that HPV testing. To further substantiate this 
we wondered whether in women treated for high grade CIN recurrence of high grade CIN was 
associated with certain HPV genotypes. In Chapter 6 we analysed the presence of HPV 
genotypes in relation to recurrence of high grade CIN in women who underwent treatment for 
CIN2+ lesions. . We found that the post-treatment CIN3 rate is increased in HPV16-positive 
women treated for CIN3. 
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Finally, in Chapter 7 we put the data from the chapters into perspective and describe in 
more detail our findings in relation to possible implementation of self-sampling for hrHPV testing 
in primary cervical screening.  
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Abstract 
 
Background Despite programmed screening in The Netherlands, the decrease in incidence of 
cervical carcinoma lags behind. We analysed screening preceding carcinoma cases, timeliness 
in case of follow-up and FIGO stages as efficiency parameters for screening.  
 
Methods We analyzed 286 women with cervical cancer between 2005–2007 for cytology history 
preceding carcinoma, hierarchically arranging cytology history (if present) into three groups: 
‗screened‘, ‗work-up‘ and ‗underscreened‘, (>6 yrs prior to diagnosis). For screen- and work-up 
smears we analyzed timeliness. FIGO stage were measured in relation to cytology history.  
 
Results 99/286 (36.7%) women with cervical carcinoma were screened preceding the 
diagnosis. Delayed time-intervals in case of abnormal cytology was 43.5% for BMD and 38.0% 
for >BMD (p=0.51). 104/286 (36.4%) women were underscreened and 73/286 (25.5%) were 
unscreened. Advanced carcinoma or FIGO stage >2B in screened women was 16.0% versus 
48.7% in work-up, underscreened or unscreened (p<0.001). 
 
Conclusion Women with cervical cancer are underscreened and have poor timeliness in case 
of abnormal cytology. Being un- or underscreened correlates significantly with higher cervical 
cancer stages, especially in older women (aged >49 years; p<0.001). Improvement of 
attendancy is needed to meet the standards of quality for screening programmes. 
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Introduction 
Cervical cancer is preceded by well defined premalignant lesions which can be identified 
by detecting abnormal cells in Papanicolaou (Pap) smear. Cervical screening by cytology with 
adequate treatment have resulted in a decrease in incidence and mortality of cervical 
carcinoma.(113;114) In the Dutch screening programme women aged 30-60 years are invited 
every 5 years, 7 times a lifetime. Modelling, prior to the introduction of the Dutch cervical 
screening programme, predicted a decrease in cervical carcinoma by approximately 75%, 
assuming full coverage(44), within the range mentioned in other studies.(4;115)  
Coverage of the screening programme is currently 77%.(50) 65% of women attend the 
screening programme after an invitation, referred to as smears made inside the screening 
programme and 12% reflects smears made outside the screening programme (opportunistic 
smears). Approximately 23% of the invited women will not be screened at all.(85) Collectively, 
the effect on carcinoma incidence through these two modes of screening will be lower than 
modelled for the programme since full coverage is not attained. Moreover, the non-participating 
fraction of women (referred to as non-attendees) has a higher risk for cervical carcinoma than 
average, thus further decreasing the effectiveness of a programme in reducing carcinoma 
incidence.(116) Earlier studies have shown that 40-50% of the women diagnosed with cervical 
cancer are in the non-compliance group.(55;117)  
Here we analysed 286 women with cervical carcinoma from the region Noord-
Holland/Flevoland in the Netherlands diagnosed between 2005-2007 We analysed the 
relationship  between the FIGO stage of the detected  carcinoma and the associated  screen 
status. In addition, we analysed whether the smear was made within or outside the screening 
programme, and the compliance for referral to the gynaecologist in case of an abnormal smear. 
 
Methods  
Data of regional carcinoma cases from PALGA 
All cytological and histological results carried out in The Netherlands are excerpted in the 
Pathological National Automated Archive (PALGA), a centralised database. Since 1991, 
coverage is at least 95%.(118) We linked patient records based on identity of the encrypted first 
four letters of the maiden name and date of birth. The ‗twinning-rate‘ is estimated to be around 
2% per record.(119)  
In total, our query in PALGA yielded 337,830 numbers of smears of which 334 cases 
(0.10%) with index-diagnosis histologically-confirmed cervical carcinoma in the years 2005-
2007, and living in one region of the Netherlands. Groups of records presumably belonging to a 
single person were ‗eyeballed‘ (checking every case manually) to filter out administrative twins 
by checking domicile, initials, and apparent inconsistencies in clinical history (n=48). This left 
307,298 numbers of smears, of which 286 (0.09%) women were diagnosed with histologically-
confirmed cervical carcinoma. Cervical smears were registered as either inside- or outside the 
screening programme. This study was approved by the ethical committee of PALGA 
(Pathological National Automated Archive). 
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Definition of „cytology history‟ in this analysis 
Screening histories of the 286 cases of carcinoma from PALGA database were analyzed 
for presence or absence of cytology history. For each woman, we took the moment with cervical 
carcinoma-diagnosis (t=0). From this point, we did a retrospective research in the preceding time 
period to determine their last cytological examination. Three timeframes were defined, 
‘unscreened‘ (no smear at all prior to the diagnosis of cervical carcinoma or only work-up smear 
prior to the diagnosis), ‗underscreened‘ (last smear taken >6 years prior to the diagnosis – the 
work-up smear not included) or ‗screened‘ (smear taken between 1 year and <6 years prior to 
the diagnosis). We defined cytology obtained less than 1 year preceding the diagnosis as a 
‗work-up smear‘.  
The choice of this time-period is based on the once-every-5-years-invitation of the Dutch 
screening programme protocol, which means that all women between 30 and 60 years of age 
are invited for programmed screening every 5 years, which is sent for free of charge for cytology. 
In relation to this interval, we have defined in our analyses the screening episode with an interval 
period of 6 years prior to the diagnosis of cancer until 1 year prior to the diagnosis. If a smear is 
detected in the database within this period, we consider the women ‗screened‘. Our three 
defined timeframes were categorized hierarchical: first, a woman was considered ―screened‖ if 
she had a smear taken in this 1 to <6 year period. Secondly, a woman was considered 
―underscreened‖ if she had a smear >6 years prior to the diagnosis, but not in the screened 
period. Thirdly, a woman was considered ―unscreened‖ if she had only a work-up smear or had 
had no smear at all in the past. Because of this hierarchical categorization, the women with a 
smear in the screened period could also have smears in the period >6 years prior to the 
diagnosis, and/or a work-up smear. Furthermore, women categorized underscreened could also 
have work-up smear. 
Age stratification was done in nine groups of 5 years (i.e. <29 years of age, 29-33 years 
of age, 34-38 years of age, 39-43 years of age, 44-48 years of age, 49-53 years of age, 54-58 
years of age, 59-63 years of age, and >63 years of age). Subanalysis of smears was based on 
the mode (i.e., invitational or inside the screening programme or outside the screening 
programme). For this subanalysis of ‗within the screening programme‘, we have chosen for 
upper age 63, since the Dutch screening programme invites women up to age 60 (with a cut-off 
at 63 due to a possible follow-up time) and for lower age 29 years since women can be invited 
from the age of 29 years onwards. The number of eligible women (29-63 years of age) was 217 
women for this subanalysis with respect to the screening programme (Figure 1).  
In case of multiple abnormal smears in the screening history (e.g. in case of repeat 
cytology after BMD), we accepted the first abnormal smear as starting point. If women had only 
multiple normal smear results in the screened period, we analyzed the time-interval between the 
last smear prior to the diagnosis and the time of diagnosis. All analyses were performed using 
SPSS 15.0 software. 
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Aged >64 years
n=63 / 286 (22.0%)
CxCa
n=286
Aged <28 years
n=6 / 286 (2.1%)
Aged 29-63 years
n=217 / 286 (75.9%)
Last smear <1 years
n=5
Screening programme
n=106
Outside screening 
programme
n=74
No smear in the past 
n=35 / 63 (57.1%)
Last smear <1 years
n=29
Last smear between >1 
and <6 years
n=75
Last smear between >1 
and <6 years
n=24
Last smear >6 years
n=2
Last smear <1 years
n=49
Last smear >6 years
n=1
Last smear <1 years
n=21
Last smear between >1 
and <6 years
n=6
Last smear >6 years
n=1
No smear in the past 
n=37 / 217 (17.1%)
No smear in the past 
n=1 / 6 (16.7%)
n=180 n=28n=5
Figure 1: Flowchart of women with cervical carcinoma (stratified by 3 age groups, mode of 
screening, and cytology history). The flowchart is based on non-hierarchical categorisation of the 
cytology history. 
 
 
 
 
 
Definition of work-up smear in this analysis 
Work-up smears for diagnosis were defined as all cases of cytology obtained <1 year 
prior to the diagnosis rather than 6 months, because we considered women with a >BMD 
preceded by BMD cytology in the period of 12 to 6 months prior to the diagnosis, to represent 
women who should have had a severe abnormality in the first smear and thus be representative 
for women with signs and symptoms of carcinoma. We have taken this into account plus 
allowing a few months delay in repeat. Thus, we end the period for work-up smears at 1 year 
prior to the diagnosis.  
 
Screening programme in the Netherlands and eligibility  
Women are invited in the Netherlands in the year they become 30 years of age. Actually, 
at the time of screening they may still be 29 years of age. Similarly: at the second invitation, 
women may be still 34 years of age. 
Women with a normal smear results will be invited again in the next screening round. 
Women with borderline/mild dyskaryosis (BMD) are advised to repeat the smear after 6 and 18 
months. If at least one of the repeated cytology smears is read as BMD or worse, the woman will 
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be referred to a gynaecologist for colposcopy. Women with >BMD are referred immediately to a 
gynaecologist. Women with inadequate smears (not suitable for diagnosis) are advised to repeat 
the test after 6 weeks. 
 
Time-interval between abnormal smear and diagnosis of cervical carcinoma 
Among these women with cervical carcinoma we analyzed the time-interval between the 
first abnormal smear cytology and the histologically confirmed diagnosis. For timeliness, women 
were categorized as ―not delayed‖ or ―delay in diagnosis‖ (see Table 1 for definitions of 
timeframes). Smears with BMD that led to the histologically confirmed diagnosis <24 months, 
were considered as ―not delayed‖. For smears with >BMD, timeliness was set on <6 months, as 
described by Bos et al.(55) For time-interval computations, all women with a smear taken up to 6 
years (-2192 days) prior the diagnosis, were included in these analyses (thus encompassing 
both the screened group as the work-up group: n=195). Two cases with inadequate smears 
without follow-up were excluded, leaving a total of 193. After tabulating smear results, the time-
interval was categorized in 2 periods: not delayed and delay in diagnosis. 
 
Table 1: overview of the definitions in this manuscript: screen smear (screening episode), work-up 
smear, diagnosis delay in diagnosis and screening interval. 
 
Definition Description 
Screen smear
1
 Smear taken between 1 year and <6 years preceding to 
diagnosis 
 
Work-up smear Smear taken maximum 1 year preceding to diagnosis 
screening interval Dutch programme Once every 5 years (between the age 30-60 years) 
“delay” in diagnosis Interval between last smear and diagnosis 
Delay for borderline mild dyskaryosis (BMD  Cytology> 18 months preceding to diagnosis 
Delay for worse than BMD (>BMD)  Cytology > 6 months preceding to diagnosis 
1 
screen smear : smear taken in this period is considered as ―screened in screen period or screen 
episode‖. 
 
 
 
FIGO stage of cervical carcinoma related to cytology history and mode of screening 
The FIGO stage of cervical carcinoma was related to the cytology history (i.e. presence 
or absence of a smear). Absence was defined as having no smear in the screened period. 
Furthermore, we also analysed the FIGO stage in relation to the cytology result of women with a 
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smear taken in the screened period allowing insight in whether an inadequate cytology advice 
results in a later detection of carcinoma. Both types of analyses were stratified by age eligibility 
for screening invitation, or other ages. These analyses were also stratified by age (see Figure 2). 
The analyses were done with the Fisher‘s exact test.  
 
Results 
Cases cervical carcinoma  
The final query result from PALGA for the years 2005-2007 yielded 286 cases after 
excluding 48 cases due to double counting twinning, too late a diagnosis (i.e. in 2008), 
carcinoma of endometrial origin or metastasis. Age ranged between 25 and 93 years old (mean 
age: 50.8 years). We divided the remaining 286 women into an eligible group (n=217, aged 29-
63) for receiving an invitation within the context of a screening programme, and a non-eligible 
group (i.e., aged <29 years (n=6), or >63 years (n=63), for falling outside invitational cohorts. 
The number of women without any smear in the period preceding the diagnosis was 1/6 
(16.7%), 37/217 (17.1%), and 35/63 (55.6%) for women aged 29 years, 29–63 years, and >63 
years, respectively (n=217; see Figure 1).  
 
Figure 2: Women with histologically confirmed cervical carcinoma; the FIGO stage in relation to 
their screen smear, stratified by age cohort. Each age cohort contains two columns, of which the 
left columns presents women without a smear in the screened period (1 year - <6 years preceding 
diagnosis), and the right columns presents smear taken within this period. 
 
Scr = Smear taken between 1and 6 years prior to the diagnosis) 
Uns = No smear taken between 1and 6 years prior to the diagnosis 
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Cytology preceding carcinoma cases: un(der)screened, screened or work-up smears 
The hierarchically categorized table 2 shows that the number of women in the screened 
period is 105/286 (36.7%). In addition 18/286 women (6.3%) were underscreened (i.e., no smear 
between 1 year and <6 years). Furthermore, 90/286 (31.5%) only had a work-up smear, and, 
73/286 women (25.5%) had no smear at all prior to the histologically confirmed diagnosis. The 
latter two groups represents the group of unscreened women. As can be seen in the one but 
lowest row of table 2, a subanalysis for women eligible for screening programme invitation, 
showed that 180/217 (99+16+65) women (82.9%) had at least a smear anytime preceding the 
diagnosis. This percentage was composed of 45.6% for ‗screened‘ and 37.3% (7.4%+30.0%) for 
‗underscreened‘ and work-up smear. A total of 37/217 (17.1%) were ‗unscreened‘, and had also 
no work-up smear prior to the diagnosis. 
 
Table 2: The cytology history (hierarchical ordered into smear taken between 1yr – 6 yrs, smear >6 
yrs, <1 yr or no smear) of women with histologically confirmed cervical cancer diagnosis between 
2005 – 2007, stratified by age-cohort. 
 
†  
smear taken <1 year prior to the diagnosis is considered as work-up smear for diagnosis 
‡
  women 29-63 years of age with non-attendancy possibility in the previous programmed screening round. 
 
Screen smear (i.e., 
between 1yr – 6 yrs) 
 
Smear taken 
>6 years 
Smear taken  
<1 year
 †
 
No smear  Total 
Age cohort N (% of row totals)  
N (% of row 
totals) 
N (% of row 
totals) 
  
N (% of row 
totals) 
< 28 years -  - 5 (83.3%)  1 (16.7%)  6 (2.1%) 
29-33 years 6 (30.0%)  - 11 (55.0%) 3 (15.0%)  20 (7.0%) 
34-38 years 23 (56.1%)  - 12 (29.3%) 6 (14.6%)  41 (14.3%) 
39-43 years 28 (54.9%)  5 (9.8%) 10 (19.6%) 8 (15.7%)  51 (17.8%) 
44-48 years 14 (43.8%)  3 (9.4%) 11 (34.4%) 4 (12.5%)  32 (11.2%) 
49-53 years 11 (32.4%)  3 (8.8%) 11 (32.3%) 9 (26.5%)  34 (11.9%) 
54-58 years 9 (42.9%)  4 (19.0%) 6 (28.6%) 2 (9.5%)  21 (7.3%) 
59-63 years 8 (44.4%)  1 (5.6%) 4 (22.2%) 5 (27.8%)  18 (6.3%) 
> 64 years 6 (9.5%)  2 (3.2%) 20 (31.7%) 35 (55.6%)  63 (22.0%) 
Total  
(aged 29-63 yrs)
‡
      
99 (45.6%)  16 (7.4%) 65 (30.0%) 37 (17.1%)  217 (100%) 
Total 105 (36.7%)  18 (6.3%) 90 (31.5%) 73 (25.5%)  286 (100%) 
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Cytology results in relation to cytology history 
Table 3 shows the cytology results of historical smears. Interestingly, 69 of 105 women 
(63.8%) who were screened between 1 year - <6 years, had a normal or inadequate (n=2) 
cytology respectively. Furthermore, 15/105 (14.3%) had >BMD, but cervical cancer was 
diagnosed more than a year later suggestive of time delays. For women with only a work-up 
smear preceding the diagnosis, the results show a different pattern: >BMD was found in 75/90 
women (83.3%). The results of cytology in the group of women screened >6 years prior to the 
diagnosis resembled the first group: 12/18 women (66.7%) had a normal cytology result, 5/18 
women (27.8%) had BMD cytology result and only 1/18 (5.6%) had >BMD (Table 3).  
In addition we have subdivided  our group of underscreened women (n=18) with respect 
to the time interval between the last negative smear and the diagnosis of carcinoma into a 
subgroup with the  last smear made 7-11 years for diagnosis and a group with the last smear 
made > 11 year for diagnosis. We could not find a significant difference in cytology result. 
However it should be realised that the number of women in the subgroups was very small for a 
meaningful analysis. 
 
 
Table 3: Screen smears, smears taken more than 6 years ago and work-up smears in women with 
histologically confirmed cervical cancer diagnosis arranged according to cytology results. 
 
 
Screen smear( i.e.,  
between 1yr – 6 yrs) 
 Smear taken 
>6 years 
Work-up smear 
(<1 year)
 †
 
No smear 
at all 
 
Total 
Cytology 
Number 
(% of column totals) 
 Number 
(% of column 
totals) 
  Number 
(% of column      
totals) 
  
Number 
(% of column 
total) 
>BMD 15 (14.3%)  1 (5.6%) 75 (83.3%) N/A  91 (31.8%) 
BMD 21 (20%)  5 (27.8%) 11 (12.2%) N/A  37 (12.9%) 
Normal 67 (63.8%)  12 (66.7%) 2 (2.2%) N/A  81 (28.3%) 
Inadequate 2 (1.9%)  - 2 (2.2%) N/A  4 (1.4%) 
No smear N/A  N/A N/A 73 (100%)  73 (25.5%) 
Total 105 (100%)  18 (100%) 90 (100%) 73 (100%)  286 (100%) 
 
†  
smear taken <1 year prior to the diagnosis 
 
 
 
 
 
 
48 
 
Diagnosis of work-up smear in women with normal cytology results in the screened 
period  
The normal (n=67), and inadequate (n=2) cytology results of women in the screened 
period, as shown in Table 3, does not exclude the possibility that these women had a work-up 
smear as well (since our analysis is hierarchical). Of the 69 women, 41 subsequently had >BMD 
(incl. the 2 women with inadequate cytology smear; 59.4%), and 9 had BMD (13.0%) as work-up 
smear. Furthermore, 2/69 (2.9%) and 1/69 (1.4%) had normal cytology or inadequate cytology, 
respectively. The remaining 16/69 women (23.2%) had no work-up smear. When further dividing 
these 53 work-up smears by the mode of screening (―within screening programme‖ and ―outside 
screening programme‖), the mode was not significantly different: 26/53 women (49.1%) with a 
work-up smear were found within screening programme versus 27/53 (50.9%) outside the 
programme.  
In addition, we analysed possible work-up smears from women with >BMD and BMD in 
the screened period. Twelve of 15 women (80.0%) with >BMD in the screened period, again had 
>BMD, 1 woman (6.7%) had BMD and 2 women (13.3%) had no smear in the work-up for 
diagnosis period (not shown). Similarly, for women with BMD in the screened period, 13/21 
(61.9%) had >BMD, 3/21 (14.3%) had BMD,1 woman (4.8%) had a normal cytology result and 4 
women (19.0%) had no smear in the work-up period. Again, the distribution of the indication 
smear is equal for both groups (data not shown).  
 
Screen smear and work-up smear in women with carcinoma in relation to mode of 
screening 
For the subanalysis of cytology history in relation to the mode of screening (stratified by 
age-cohort), only women eligible (n=217) for programmed screening (aged 29–63 years), and 
having at least one smear <6 years before diagnosis (either screen smear or work-up smear. 
For definitions see Table 1), were selected (see Table 4). Screen smear and work-up smear are 
denoted separately. In addition, 14/18 women (77.8%) who were categorized as underscreened, 
also had a work-up smear and were therefore included. The remaining 4 women from this group 
were added to the 73 women without any smear prior to the diagnosis, since a work-up smear 
was lacking. 
Only 99 of 217 women (45.6%) actually had a smear taken in the screened period 
(p<0.001), of whom 75/99 (75.8%) had a programmed smear and 24/99 (24.2%) had the smear 
taken outside the screening programme, which was statistically significant (p<0.001).  
A further 78/217 (35.9%) women had a work-up smear only, divided between 29/78 
(37.2%) (aged 29–63 years) for invitational cytology, and 49/78 (62.8%) outside the screening 
programme (see Table 4 and Figure 1). In total, 40/217 (18.4%) had no smear at all <6 years 
prior to the diagnosis.  
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Timeliness between first abnormal cytology smear and histologically confirmed 
carcinoma 
Table 5 shows the timeliness between the first abnormal smear and histologically 
confirmed cervical cancer between 2005–2007 (stratified by cytology result: >BMD or BMD). We 
included all cytology taken up to 6 years prior to the diagnosis (thus both screen smear as well 
as work-up smear), which resulted in total 142 >BMD and 46 BMD cases. As shown previously 
in Table 3 shows that 15 and 21 women with cytology in the screened period, had >BMD, and 
BMD, respectively. Furthermore, cases with >BMD work-up smear of women who had had a 
normal or inadequate cytology smear in the screened period before diagnosis were included (41 
and 9 of 69 women had >BMD, and BMD, respectively). 
 
 
Table 5: Timeliness of abnormal (“>BMD” or “BMD”), and normal smear preceding cervical cancer. 
All smear types (smear and work-up smears).  
 
Cytology Total  Not delayed  95% CI 
>BMD
1 
142 (100%) 88 (62.0%)  53.5 – 70.0 
BMD
2 46 (100%) 26 (56.5%)  41.1 – 71.1 
Total 188
3
 (100%) 114 (60.6%)  53.3 – 67.7 
 
1
 maximum time-interval between the first abnormal smear and histologically confirmed CxCa was 6 months (a 
longer time-interval was considered as delay in diagnosis). 
 
2
 maximum time-interval between the first abnormal smear and histologically confirmed CxCa was 24 months 
(a longer time-interval was considered as delay in diagnosis). 
 
3 
In total 73 of 286 women had no smear at all preceding to diagnosis, leaving 213 cases with a smear. 25 of 
these 213 women had only normal cytology (n=23) or time-information was lacking (n=2), leaving 188 cases 
to analyse. This consisted of >BMD or BMD as follows: in the screen period 15 and 21 women had >BMD 
and BMD, respectively (see table 3). In the work-up period group, 75 and 11 women had >BMD and BMD, 
respectively. Furthermore, 41 and 9 women who had a normal smear result in the screen period, had >BMD 
and BMD, respectively, as work-up smear. Finally, for women who had a normal smear result in the 
underscreened period (n=12), 10 women had >BMD as work-up smear (The remaining 2 woman had normal 
smear result again). Another 1 - and 5 women had already >BMD and BMD, respectively, in the 
underscreened period (see Table 3). This results in a total of 142 >BMD, and 46 BMD (total n=188).  
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For timeliness, we divided the interval in ‗not delayed‘ and ‗delay in diagnosis‘ (see M&M 
for definitions). In the group of women with >BMD cytology smear, 88/142 (62.0%; 95% CI 53.5 
– 70.0) showed no delay for diagnosis. In the group women with BMD, 26/46 (56.5%; 95% CI 
41.1 – 71.1) had no delay in diagnosis. Delay in diagnosis for women with >BMD, and BMD 
were observed in 54/142 (38.0%), and 20/46 (43.5%), respectively. Overall, 60.6% of the 
women had no delay in diagnosis (95% CI 53.3 – 67.7). The difference in delay in diagnosis of 
between women with >BMD and BMD cytology smear was not significantly lower (p=0.51). 
We also analyzed the work-up smears of women who had a normal smear (12 of 18 
women; 66.7%) in the period >6 years before the diagnosis. In total 10 of these 12 women had 
>BMD (83.3%) and 2 of 12 women (16.7%) had again normal cytology result. The 6 of 18 
women with >BMD result (1 woman with >BMD, and 5 with BMD) >6 year before diagnosis 
were, categorized as delay in diagnosis. Together with the 75 women with >BMD, and 11 
women with BMD, the total >BMD, and BMD cases are 142 and 46, respectively. For the 
remaining 25 women timeliness was not applicable, since they had had either normal cytology 
(n=23) or time-information was lacking (n=2). 
 
FIGO stage of cervical carcinoma in relation to cytology history 
In Table 6a, we show the FIGO stage in relation to the cytology history. The FIGO stage 
was grouped into low grade (1A or 1B), borderline (2A-2B) and high grade (>3A), because this 
grouping has consequences for therapy, and gives more relevant information about the relation 
between FIGO stage and screening history. FIGO stage information was available for 90.2% 
(258/286) of the cases, of which 196 and 62 in the group of women aged 29-63 years, and <29 
years/>63 years respectively. Most women had no cytology smear taken in the screened period 
(158/258; 61.2%, 95% CI 55.3% - 67.2%), leaving 100 women with a smear taken in the 
screened period with a known FIGO stage in this group for analyses. In total 18 of 34 women 
(52.9%) with FIGO stage 1A had screen smear. Furthermore, 58 of 95 women (61.1%), 15 of 42 
women (35.7%), and 3 of 25 women (12.0%) with a screen smear had 1B, 2A-2B, and 3A-4 
FIGO stage, respectively.  
When comparing the FIGO stage 1A to 1B, there is statistically no difference (p-value 
0.424) in the percentage of screen smear. However, when we compare FIGO stage group 1B to 
2A-2B, we notice a significant difference (p-value 0.009). Also a difference can be noticed when 
we compare the group 2A-2B to 3A-4 (p-value 0.047). Overall, the group with high-grade FIGO 
stage had significantly lower screen smear compared to the group with low grade FIGO stage 
(p<0.001; see Table 6a).  
In the age group <29 years/>63 years, there were no significantly differences between 
the FIGO stage and having had a screen smear. Furthermore, we also analysed if a the 
differences between FIGO stage and two age-group (29-63 years vs <29 years/>63 years) was 
significant. The result showed that it was (p<0.001). 
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When we analysed FIGO stage of women with a screen smear (n=100), in 
relation to their cytology smear result (>BMD, BMD, or normal), no significant differences 
were found (see Table 6b). However, women aged 29/>63 years showed significantly 
more cytology lesions than women aged 29-63 years (p<0.001; data not shown). 
We then analysed FIGO stage in relation to screen smear vs. otherwise per age 
strata (see Figure 3). We noticed a trend of more severe FIGO stage (FIGO stage >2B) 
among older women (aged 49 years and older; n=56/89; 62.9%) who had no smear in 
the screened period, compared to women who had their smear in the same period 
(n=8/33; 24.2%, p<0.001). In addition we analysed if a correlation could be found 
between the mode of screening and severe FIGO stage found among women (aged 34-
63 years) who had their smear in the screened period. No statistically difference was 
found (p=0.822; data not shown). 
 
Discussion 
Our data show that only 36.7% (105/286) of women diagnosed with cervical 
carcinoma in the region Noord-Holland/Flevoland between 2005-2007 were 
appropriately screened. If restricted to eligible women for receiving an invitation for 
cervical screening (aged 29-63 years), this percentage was 45.6% (99/217). This finding 
is in agreement with a meta-analysis study, showing that about 46.2% women had a 
smear in the screened period.(120)  
Further analysis showed that 67/105 women (63.8%) that were ‗screened‘ had a 
normal cytology result (table 3). A meta-analysis study had an outcome of 29.3% of 
women with at least one normal cytology result in the same period.(120) However, 48 of 
the 67 (74.5%) women in our study subsequently had abnormal cytology (>BMD) in their 
work-up smear, as assumed in previous modelling. Only 2 women (3.9%) had again a 
normal smear result in the work-up smear period. Even within the context of the limited 
reproducibility of cytology, this change from normal cytology to abnormal cytology in 
women with subsequent histologically  proven cancer is likely to be caused by 
inappropriate sampling, processing or erroneous reading of the cytology.  
Furthermore, our data show that 75/217 (34.5%) women from the eligible age 
cohorts, had been screened within the screening programme (see Table 4) in the 
appropriate period preceding the carcinoma diagnosis. From the residual 142, 29 were 
possibly ‗screen detected‘ within the programme (13.4%), but were underscreened. The 
remaining 113/217 eligible women either did not have cytology <6 years preceding 
diagnosis (underscreened period; 40/217; 18.4%), or had obtained a smear outside the 
programme (73/217; 33.6%). These data shows that the detected histologically-
confirmed carcinoma rate was higher among women who had not sufficiently attended 
organised screening (142/217) in the screened period (65.4% vs. 34.6%. p<0.001; See 
Table 4). 
The results of timeliness between the first abnormal smear <6 years preceding 
the diagnosis and histologically confirmed diagnosis showed 62.0% (95% CI 53.5% - 
70.0%) no delay in diagnosis among women with >BMD as cytology diagnosis and 
56.5% (95% CI 41.1% – 71.1%) among women with BMD (p=0.51). This suggests that 
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significant improvements can be made in both compliance with repeats as well as 
redressing delays in workup. 
The correlation between the FIGO stage and women with or without a cytology 
smear in screened period showed a difference for higher stages: a 1.7-fold higher 
cervical carcinoma stage (stage 2A-2B) was observed in carcinoma bearing women 
(aged 29-63 years) without cytology history, compared to women with 1B FIGO stage 
(p=0.009), while 1.4-fold higher cervical carcinoma stage (stage 3A-4) was found among 
women without screen smear, compared to women with screen smear and had 2A-2B 
FIGO stage (p=0.047). Furthermore, a trend can be seen in the relation between the 
higher stages and age of women. The older women (age >49 years) without a smear in 
the screened period showed significantly higher FIGO stages, compared to older women 
who had a smear in the same period (p<0.001). This indicates that non-screened older 
women are at higher risk for high stage cervical cancer.  
In conclusion, our data shows that only 34.6% of all eligible women (aged 29-63 
years) had participated in organised programmed screening between 1 year and <6 
years prior the diagnosis (95% CI 28.2%–40.9%; p<0.001). Even if women screened 
outside the screening programme were included, the percentage would be 45.6%, which 
similar as reported in the literature.(120) Moreover, 67 woman had a normal screen 
smear followed by an abnormal smear in either the next round or in the work-up phase 
prior to carcinoma. These findings demonstrate both programme sensitivity as well as 
compliance need improvement. This may be achieved by implementing hrHPV testing as 
primary screening tool.(65;121-124) 
There are several options to improve participation rate of organised screening 
programme. Hermens et al. have shown that women are more willing to attend in a 
screening programme when invitations are sent by their general practitioners in stead of 
the municipality.(82) Another option to influence the effectiveness of the screening 
programme, especially with regard to timeliness, is increased computerized controls to 
support physicians in controlling follow-up.(83) Finally, we recently showed that offering 
self-sampling for hrHPV DNA testing to non-attendees in the cervical screening 
programme is a feasible and effective approach, leading both to increased coverage and 
marked detection of CIN2+/CIN3+ lesions, particularly in women who did not attend the 
previous screening round.(125)  
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ABSTRACT 
 
Objective To determine whether offering self sampling of cervicovaginal material for 
high risk human papillomavirus (HPV) testing is an effective screening method for 
women who do not attend regular cervical screening programmes. 
 
Design Cohort study (the PROHTECT trial). 
 
Settings Noord-Holland and Flevoland regions of the Netherlands, December 2006 to 
December 2007, including 13 laboratories, gynaecologists, and more than 800 general 
practitioners. 
 
Participants 28,073 women who had not responded to two invitations to the regular 
cervical screening programme: 27,792 women were assigned to the self-sampling group 
and invited to submit a self collected cervicovaginal sample for HPV testing; 281 were 
assigned to the recall control group and received a second re-invitation for conventional 
cytology. 
 
Intervention Women with a positive result on the high risk HPV test on their self sample 
material were referred to their general practitioner. Women with abnormal results on 
cytology were referred for colposcopy. Women with normal results on cytology were re-
evaluated after one year by cytology and high risk HPV testing and referred for 
colposcopy if either result was positive. 
 
Main outcome measures Attendance rate in both groups and yield of cervical 
intraepithelial neoplasia grade II/III or worse (≥CIN II/≥CIN III) in self sampling 
responders. 
 
Results The compliance rate in the self sampling group was significantly higher than in 
the control group (crude 26.6% v 16.4%, P<0.001; adjusted 27.5% v 16.6%, P<0.001). 
The number of detected ≥CIN II and ≥CIN III lesions in self sampling responders was 99 
(1.3%) and 76 (1.0%), respectively. Self sampling responders who had not participated 
in the previous round of screening (43%) had increased relative risks of ≥CIN II (2.04, 
95% confidence interval 1.27 to 3.28) and ≥CIN III (2.28, 1.31 to 3.96) compared with 
self sampling women who had been screened in the previous round (57%). 
 
Conclusions Offering self sampling by sending a device for collecting cervicovaginal 
specimens for high risk HPV testing to women who did not attend regular screening is a 
feasible and effective method of increasing coverage in a screening programme. The 
response rate and the yield of high grade lesions support implementation of this method 
for such women. 
 
Trial registration ISRCTN45527158. 
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INTRODUCTION 
The introduction of organised cervical cancer screening programmes in Western 
countries has contributed to a decrease in incidence of and mortality from cervical 
cancer. Nevertheless, one major problem concerning the effectiveness of current 
cervical screening programmes remains non-attendance.1-4  
Non-participating women (that is, non-attendees) are at increased risk of cervical 
cancer.56 Therefore, targeting non-attendees is important in achieving optimal 
protection from screening programmes. Offering self sampling of cervicovaginal material 
for screening has been suggested as a way of increasing screening compliance.1,7,8 
Cytomorphological evaluation of self sampled cervicovaginal specimens for 
detection of high grade cervical lesions has been shown to be inferior compared with 
cervical samples obtained by a physician. Conversely, high risk HPV testing on self 
collected cervicovaginal samples had at least similar sensitivity for cervical intraepithelial 
neoplasia grades II/III or worse (≥CIN II/≥CIN III) compared with cytological reading of a 
corresponding cervical sample collected by a physician.9-12 
 
 
METHODS 
Patients and procedures 
 
PROHTECT (protection by offering HPV testing on cervicovaginal specimens 
trial) is a cohort study within the setting of the Dutch population based cervical screening 
programme to assess the feasibility and efficacy of offering cervicovaginal lavage self 
sampling for high risk HPV testing to women who do not attend the regular screening 
programme. In the Dutch screening programme, women aged 30-60 are invited once 
every five years. Non-attendees living in the counties of Noord-Holland or Flevoland 
(n=28,073) who had received their screening invitation in 2005 were selected from the 
regional health council registry. In the screening programme women are asked to make 
an appointment to have a smear taken by their general practitioner or assistant. 
Opportunistic smears are disregarded but results are registered in the nationwide 
pathology database (PALGA). There is no charge for women participating in primary 
cervical screening, but the costs for the necessary follow-up in cases of abnormal 
cytology can be recovered from health insurance companies. A ―non-attendee‖ was 
defined as a woman who neither responded to the regular invitation nor to a standard 
reminder after six months. Women with previous hysterectomy were excluded. 
With a computerised random number generator non-attendees were assigned in 
a 99:1 ratio to either receive a kit (Delphi Screener (previous Pantarhei-
Screener/Mermaid)) to collect cervicovaginal material for subsequent testing for high risk 
HPV hybrid capture II (self sampling group, n=27,792) or to receive a second recall for 
conventional cytology (recall control group, n=281). The Delphi Screener is a lavage 
device, designed to rinse the upper vagina and cervix and, in combination with HPV 
testing, has been shown to allow detection of similar high grade yields of CIN to those 
achieved in cervical smears collected by physicians.9 The skewed ratio ensured 
 62 
adequate power to detect a higher attendance rate in the self sampling versus second 
recall arm, while at the same time maximising the ≥CIN II/≥CIN III rate among self-
sampling responders. The pre-randomised self sampling and recall cohorts were 
recruited from December 2006 to April 2007, and women were invited to respond within 
six weeks after the mailing. Only responses received up to December 2007 were scored 
for analysis. 
All invited women were written to at their home address the week before to give 
notice of receipt of a second recall letter (recall control group) or a self sample kit (self 
sampling group). Women in the recall control group received an official second reminder 
to visit their general practitioner for conventional cytology, an explanatory letter, and an 
informed consent form. Women in the self sampling group received a self sample kit with 
an explanatory letter, a collection tube, instructions (written and drawn), an informed 
consent form, and a return box with the address of the testing laboratory. A telephone 
helpline and website providing information on the trial (www.hpvthuistest.nl) was 
available throughout the study. 
HPV testing and follow-up algorithm Women in the self sampling group were 
asked to send the collection tube containing their cervicovaginal lavage specimen with 
the signed informed consent form to the laboratory for high risk HPV testing. Each 
specimen was tested with the hybrid capture II high risk HPV DNA method at the 
laboratory. The results of the confirmatory HPVsamples taken by general practitioner 
(see below) were also based on the hybrid capture II tests. On arrival in the laboratory, 
lavage specimens were concentrated by spinning down, removing all supernatant, and 
resuspending the pellet in universal collection medium. If no clear cell pellets were 
visible, samples were considered invalid for testing. In such cases, the woman was sent 
a second kit to repeat the self sampling at home. Valid samples were subjected to the 
hybrid capture II high risk HPV DNA test in an automated format on a rapid capture 
system), according to the manufacturer‘s instructions (Qiagen, Gaithersburg, MD, USA). 
This test is designed to detect high risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, and 68. Results were expressed as relative light units per cut-off value 
(RLU/CO). Women with a positive result (RLU/CO ≥1) were instructed to visit their 
general practitioner for their doctor to take a cervical sample for cytology and 
confirmatory HPV testing in the regional laboratory serving the general practitioner. 
Women with abnormal cytology results (threshold borderline or mild dyskaryosis) were 
referred for colposcopy. Cytology of cervical smears taken by the physician was carried 
out in local laboratories, and results were reported according to the CISOE-A 
classification, the standard classification system for cytology in the Netherlands, which 
can easily be translated into the Bethesda classification.10 In brief, on the basis of either 
squamous or columnar abnormalities, cytology results are categorised into three groups 
(normal, borderline or mild dyskaryosis, and moderate dyskaryosis or worse). Borderline 
or mild dyskaryosis corresponds in the Bethesda classification to ASCUS\LSIL. 
Endometrial abnormalities were excluded. 
Independent of the HPV test result on the specimen taken by the physician, 
women with normal cytology results received advice for repeat testing (cytology and 
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HPV testing) after a year and were referred for colposcopy in case of a positive HPV or 
cytology test result (threshold ≥borderline or mild dyskaryosis). Women with negative 
results on both tests were referred back to the national screening programme as their 
risk of a clinically relevant lesion was considered too low to warrant referral for 
colposcopy.11 Colposcopy directed biopsies were taken for histological examination from 
suspected areas on the cervix according to standard procedures in the Netherlands.12,13 
Histological examination was done in local pathology laboratories and specimens were 
classified as CIN 0 (that is, within 
normal limits or including any non-neoplastic lesion such as inflammation, cyst, etc), I, II, 
or III, or as invasive cancer, according to international criteria.14,15 On the basis of biopsy 
results, women were treated in accordance with the guidelines of the national screening 
programme.16 Based on the cytology results, participating women in the recall control 
group were managed according to the guidelines of the national screening programme.17 
 
Statistical analysis 
Power calculation 
For the power calculation, we estimated the population of non-attendees in the study 
area to be 45 000 in the year 2005. We further assumed 10% of these women would not 
be eligible and that the response rate in the self sampling group would be 15% higher 
than in the recall control group. The power calculation was based on our previous pilot,1 
which showed compliance rates of 17.6% and 31.5% in the recall control and self 
sampling groups, respectively (two sided t test; α 0.05; 99:1 randomisation; power 
0.99999). We chose a 99:1 randomisation to provide sufficient power to detect 
differences in compliance and to maximise the yield of ≥CIN II/≥CIN III in the self 
sampling cohort. 
 
Response rate 
All trial data were managed within a customised database. The self sampling 
response was counted on the basis of receipt of informed consent forms plus self-
samples, and the response of the recall control group was counted on the basis of 
receipt of informed consent forms as well as through the nationwide network and registry 
of histopathology and cytopathology in the Netherlands (PALGA; Bunnik, Netherlands). 
For computing the response rate we included all women who responded actively within 
12 months after their invitation to participate in this trial and compared response rates of 
the groups with χ2 test. In addition to the crude response rates, we also compared the 
response rates adjusted for women who during the study reported they were not eligible 
because of previous hysterectomy. 
 
HPV prevalence and yield of high grade CIN and cervical cancer 
Only self sampling material sent in within a year after the invitation was included 
in HPV prevalence analysis. The 18 month cumulative yields of ≥CIN II and ≥CIN III in 
women in the self sampling group who submitted a specimen were obtained through the 
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PALGA database. If necessary, physicians were contacted directly for additional clinical 
data. 
 
Assessment of screening history self sampling responders 
Programmed screening in the Netherlands involves seven cytology invitations 
during a lifetime to women aged 30-60—that is, every five years. The PALGA database 
provided the screening history of attendees in the two groups.18 In analysing the 
screening history among the women who had been invited for a previous round of 
screening (that is, those aged ≥34), women were considered to have missed the 
previous screening round if a smear sample had not been taken within the past seven 
years. 
Risks of ≥CIN II and ≥CIN III were calculated for women aged ≥34 who did not 
participate in the previous round relative to those who were screened in the previous 
round. The relative risks were adjusted for age by the Mantel-Haenszel method, with age 
stratified at 34-38, 39-43, 44-48, 49-53, 54-58, and ≥59. Women aged ≤33 could not 
have a screening history because of their age and were excluded. The association 
between the relative risks and age, as well as between the relative risks and screening 
history, were tested by the Mantel-Haenszel test of homogeneity. 
 
 
RESULTS 
Characteristics of trial cohort 
 
Figures 1 and 2 show the flow of women through the study. The public health 
database indicated that 28,073 women in the 2005 cohort who received an invitation to 
screening in the study area were registered as nonattendees, instead of the expected 
45,000. Of these, 27,792 were allocated to the self sampling arm and 281 to the recall 
control arm. During the study 906 women (3.3%) in the self sampling group and four 
women (1.4%) in the recall control group reported having had a hysterectomy, leaving 
26,886 eligible women in the self sampling group and 277 in the recall control group. 
There were no significant differences between the age distributions in both arms. 
 
Participation rate 
In the self sampling group, 7404 of 27 792 (26.6%) women sent a self sampled 
specimen for HPV testing and 51 (0.2%) decided to visit their general practitioner for 
conventional cervical cytology. When we adjusted for women who were not eligible 
because of hysterectomy, the percentage of women who responded by submitting a self 
sample was 27.5%. The self sampling response rate did not vary with age (Pearson 
χ2=7.15, df=6; P=0.307). 
 
 
 
 
 
 
 65 
Figure 1: Study design for comparison of compliance rates between recall control group 
and self sampling group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the recall control group, 46 of 281 (16.4%) women visited their general 
practitioner for cervical cytology. After adjustment for non-eligibility, the response rate 
was 16.6% (46/277). Taken together, the difference in compliance rates between the 
groups was 10.2% (26.6% v 16.4%, 95% confidence interval 5.9% to 14.6%, P<0.001) 
or 10.9% (27.5% v 16.6%, 6.5% to 15.3%, P<0.001) after adjustment for those who were 
not eligible. 
To evaluate whether screening history had an effect on participation in women 
allocated to self sampling, we compared the screening history of women in the recall 
control group (n=277) with women in the self sampling group (n=26,886). When we 
excluded women aged <33 because they could not have a screening history (49 in the 
recall control group and 3398 in the self sampling group), 228 eligible women were left in 
the recall control group and 22,988 in the self sampling group. There were 34 and 6,227 
attendees aged ≥34, respectively. Of the 228 women in the recall control group, 61 
(26.8%) had had a smear taken in the past seven years, compared with 5,967 (26.0%) 
of the 22,988 women in the self sampling group, indicating no significant differences. 
We examined the effect of having no smear in the past seven years on 
attendance of women in the recall control group compared with the effect on attendance 
in the self sampling group. In the recall control group 9.0% (15/167) of the women 
responded to recall compared with 15.8% (2694/17 021) of the women in the self  
 
 
F
ig
u
re
 2
:  
S
tu
d
y
 d
e
s
ig
n
 fo
r e
v
a
lu
a
tio
n
 o
f y
ie
ld
 o
f ≥
C
IN
 II in
 w
o
m
e
n
 o
f s
e
lf s
a
m
p
lin
g
 g
ro
u
p
 (B
M
D
=
b
o
rd
e
rlin
e
 o
r m
ild
 d
y
s
k
a
ry
o
s
is
) 
                       
 67 
sampling group. Thus, the relative risk for participation of women without a smear in the 
past seven years in the self sampling group was 1.76 (1.09 to 2.86) compared with 
women who had no smear in the past seven years in the recall control group (P=0.016). 
For the women who had had a smear in the past seven years, these proportions 
were 19/61 (31.1%) for the recall control group and 3533/5967 (59.2%) for the self 
sampling group, resulting in a relative risk of participation in the self sampling group of 
1.90 (1.31to 2.76, P<0.001). As the relative risks of participation of women who had or 
had not had a smear in the past seven years did not differ (1.90 v 1.76, P=0.80), it 
seems unlikely that screening history introduced bias in the participation of women in 
self sampling in both groups. 
 
HPV detection rate self sampling attendees 
Of the 7404 women who submitted a self collected sample, 7384 (99.8%) had a valid 
hybrid capture II test result (fig 1) and 757 (10.3%) were positive for high risk HPV (fig 
2). The percentage positive for HPV decreased with age (t=−6.77; P<0.001) until age 
39-43, when a plateau was reached (t=−0.30; P=0.77). 
Women who had positive results for high risk HPV were advised to visit their 
general practitioner for both conventional cytology and a second high risk HPV test on a 
cervical sample collected by the physician. A valid HPV result was recorded for 491, and 
288 (58.7%) were positive for cervical HPV. Of the 203 with a negative result, 81 
(39.9%) originally displayed hybrid capture II RLU/CO values <2 on the self collected 
sample. Conversely, only 21 (7.3%) with a positive result had a RLU/CO value <2 on the 
self sample. 
 
Compliance with follow-up 
Of the self sampling attendees with positive HPV results, 90.4% (684/757) 
complied with follow-up with their general practitioner. Of these 684, 437 (63.9%) 
followed the trial protocol and had both cytology and HPV test results, whereas 61 
(8.9%) had only an HPV test and 186 (27.2%) had only a cytology test. Thus 623/757 
(82%) women had cytological follow up. A total of 182 (26.6%) women had abnormal 
results on cytology, of whom 150 (82.4%) adhered to the direct referral advice for 
colposcopy. The 502 remaining women (73.4%) were advised have a repeat testing after 
a year on a sample collected by their general practitioner, and 287 (57.2%) complied. 
Based on a positive high risk HPV result or cytology result, or both, 65 (12.9%) women 
were advised to undergo colposcopy and 25 (38.5%) of them did so. 
 
Yield of high grade CIN and cervical cancer 
Among the 150 women with ≥borderline or mild dyskaryosis who visited a 
gynaecologist at baseline, 94 ≥CIN II lesions were detected, including five invasive 
carcinomas. Furthermore, five ≥CIN II lesions were detected among the 25 women who 
complied with the referral for colposcopy after repeat testing at one year. The cumulative 
18 month yields of ≥CIN II and ≥CIN III in women with a positive HPV self sampling test 
were 1.3% (99/7384) and 1.0% (76/7384), respectively (table 1). 
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Table 1: Yields of ≥CIN II/III in women who carried out cervical self sampling 
(categorised by age) 
 
Age (years) No of women No (%) with 
>CIN II 
No (%) with 
>CIN III 
< 33 1,157 29 (2.5%) 23 (2.0%) 
34 – 38 1,497 30* (2.0%) 23* (1.5%) 
39 – 43 1,266 10* (0.8%) 6* (0.5%) 
44 – 48 1,139 11* (1.0%) 8* (0.7%) 
49 – 53 918 9* (1.0%) 7* (0.8%) 
54 – 58 825 6* (0.7%) 5* (0.6%) 
> 59 582 4* (0.7%) 4* (0.7%) 
Total 7,384 99† (1.3%) 76† (1.0%) 
Total (excluding age < 33)  6,227 70† (1.1%) 53† (0.9%) 
 
 
 
Yield of high grade CIN and cervical cancer in relation to screening history 
Among women aged ≥34, those who did not have a cervical smear taken at the 
previous round had more ≥CIN II (relative risk 2.04, 1.27 to 3.28, P=0.003; table 2) and 
more ≥CIN III (2.28, 1.31 to 3.96, P=0.003; table 3) than women who did have a cervical 
smear at the previous round. This association between screening history and cervical 
intraepithelial neoplasia was not related to age (P values Mantel-Haenszel test of 
homogeneity 0.639 for ≥CIN II and 0.515 for ≥CIN III). All five carcinomas were detected 
in women aged ≥34 who had not been screened at the previous round. 
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DISCUSSION 
 
In the Netherlands in 2005, 65% of women attended the cervical screening 
programme (annual report of the regular screening programme, 2006, 
www.bevolkingsonderzoek.info/). By offering self sampling to non-attendees, and taking 
into account the 18% loss of cytology in the follow-up in this group, the real effect on 
attendance in the screening programme would be an extra 5.2% (6.3% (27.5% of 
23%)*(100%−18%)). 
The total attendance in the screening programme would then increase to 70.2% 
(5.2%+65%). Moreover, we showed that the cumulative incidence of ≥CIN II yield in our 
study was 1.3% (99/7384), while the CIN lesions found via regular screening programme 
in 2005 was 0.8% (data received from PALGA). 
 
Screening history of non-attendees  
The finding of a twofold and more than twofold relative risk of ≥CIN II and ≥CIN 
III, respectively, in self sampling women aged ≥34 who did not attend the previous 
screening round is in line with the assumption that background risk for ≥CIN II/≥CINIII is 
increased after women miss one screening round. In the self sampling group, the 
association between screening history and CIN was independent of age (P=0.639 for 
≥CIN II and 0.515 for ≥CIN III). 
 
Strengths and limitations 
We did not include a recall control group for comparison of yield of ≥CIN II/≥CIN 
III with the self sampling group because data from our previous work indicated that non-
attendees of the regular screening programme respond poorly to any repeat invitation 
letter.1 Instead, we used a randomisation ratio of self sampling versus recall women in 
favour of maximising detection of ≥CIN II/≥CIN III in the self sampling group to allow an 
accurate assessment of the yield achieved by self sampling combined with HPV testing 
in non-attendees. 
 A potential bias in our attendance data could be that, unlike responders to a re-
invitation for cytology, self sampling responders might have been more likely to respond 
for curiosity reasons, despite already being opportunistically screened before the study 
invitation. To address this we analysed the effect of screening history on participation via 
self sampling versus a second recall. When we took into account the screening history of 
women responders aged ≥34 in both arms, there was no indication that previously 
screened women would have a relatively higher preference for self sampling than 
women who were not screened within the past seven years. 
Interestingly, self sampling responders showed high adherence to direct follow-
up regimens, both at the general practitioner level (90.4%) and at the level of 
direct referral for colposcopy (94.5%). In size the latter is comparable with follow-up 
compliance of attendees of the Dutch screening programme (91%).16 Compliance after 
repeat testing advice (59% of women attended after one year), however, was markedly 
lower than observed in regular screening attendees with similar advice (86%).19 This 
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rather low return rate might be influenced by the fact that most of these women had 
previous normal cytology test results after a smear taken by a physician. 
In 41% of the women who had an HPV test on both self and physician collected 
samples, a positive result for high risk HPV in the self sample could not be confirmed in 
the sample taken by the physician. Most of these discrepant test results were found in 
women with low hybrid capture IIRLU/CO values. In self sampled specimens more HPV 
infections of vaginal origin, including those of low risk HPV types, might be detected by 
hybrid capture II.20-25 Even with a cut-off level of a positive result on hybrid capture II 
increased to RLU/CO ≥2, there are still discrepancies between positive results for HPV 
in the self sampled specimens and smears taken by the general practitioner. In that case 
the total number of HPV positive cases would decrease from 757 to 627, but we would 
miss six ≥CIN II lesions (two CIN II, and four ≥CIN III). 
Interestingly, the yields of ≥CIN II and ≥CIN III in self sampling responders who 
attended the previous round and the yields in regular screening responders of the same 
age tested for high risk HPV by general primer 5+/6+ polymerase chain reaction 
(GP5+/6+ PCR) were identical (0.8% and 0.5%, respectively).26,27 This strongly suggests 
that the ≥CIN II/≥CIN III sensitivity of HPV testing in self sampled 
Cervico-vaginal material is not inferior to that of HPV testing on smears taken by a 
physician. This is in agreement with a recent meta-analysis that indicated that self 
sampling is as sensitive as physician obtained sampling to detect high risk HPV.25   
 Collectively, our data show that targeted efforts should be made to screen self 
sampling non-attendees who missed a previous screening round, given their increased 
risk of clinically relevant cervical disease. We have also shown that the chosen triage 
algorithm of a cytology test on a conventional smear after an HPV positive self sample is 
successful. A substantial subset of the 10% self sampling women who were positive for 
high risk HPV, however, seemed to have negative cytology results and be negative for 
high risk HPV at follow-up, which in practice resulted in a marked number of 
unnecessary visits to the general practitioner for these women. Therefore, alternative 
triage tools applicable to self sampled material should be considered to prevent 
redundant sampling by general practitioners. In this context, molecular methylation 
markers,28 which are currently being investigated, are highly promising when applied to 
self sampled specimens. Furthermore, efforts are ongoing to improve liquid based 
cytological preparations of cervicovaginal lavage fluids for detecting abnormal cells. 
 
Conclusions 
It is feasible and effective to offer women who do not attend regular cervical screening 
programmes the choice of self sampling by sending a device for collecting cervico-
vaginal specimens for high risk HPV testing. This should lead to increased coverage and 
marked detection of ≥CIN II/≥CIN III lesions, particularly in women who have not 
attended the previous round of screening. Implementation is likely to pay off immediately 
in terms of protecting a subset of non-attendees 
known to be at increased risk of cervical cancer. 
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Abstract 
We evaluated the effect of offering brush-based vaginal self-sampling for high-risk HPV 
(hrHPV) testing to non-attendees of the cervical screening program on response rate, 
compliance to follow-up and CIN2+/CIN3+ yield. In addition, concordance of hrHPV test 
results between physician-taken cervical scrapes and vaginal self-samples was 
determined. 
26,409 non-attending women were randomly assigned to receive a vaginal brush device 
for hrHPV testing by HC2 (i.e., self-sampling group, n=26,145) or a re-invitation for 
regular cytology-based screening (i.e. recall control group, n=264). hrHPV-positive self-
sampling responders were invited for a physician-taken scrape for cytology and blinded 
hrHPV testing. If cytology was abnormal, women were referred for colposcopy.  
Response rate in the self-sampling group was significantly increased compared to the 
recall control group (30.8% versus 6.5%; p<0.001). The concordance rate between 
hrHPV detection in self-samples and corresponding physician-taken cervical scrape 
samples was 68.8%. Amongst women with CIN3+ and CIN2+, the concordance rates in 
hrHPV positivity between both samples were 95.5% and 93.8%, respectively. Adherence 
at baseline to cytology triage of hrHPV-positive self-sampling women (89.1%) and 
colposcopy referral of those with abnormal cytology (95.8%) was high. The 
CIN2+/CIN3+/carcinoma yields were 1.5%, 1.0%, and 0.1%, respectively, in self-
sampling responders.  
In conclusion, offering hrHPV testing on self-sampled vaginal material with a brush 
device to non-attendees significantly increases the attendance to the regular screening 
program, yields hrHPV test results that are in very good concordance with those of 
physician-taken scrapes in women with CIN2+/CIN3+, and is effective in detecting 
CIN2+/CIN3+. 
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Introduction 
In the Netherlands, an organized cervical cancer screening program with a call 
and recall system, targeting women between 30 and 60 years of age every 5 year, is 
effective since 1996. Each year, 65% of the women attend the screening program.(1) 
Together with some opportunistic screening this contributes to an overall coverage for 
cervical screening of 77%, leaving 23 % of women unscreened.(1) The effectiveness of 
the screening program is strongly dependent of the degree of attendance.(2-5) Non-
attendance is especially a problem in the youngest and oldest age groups of invitees 
(1;5). Women not attending the screening program have an increased risk of cervical 
carcinoma compared to attending women.(6) We have previously shown in the 
PROHTECT-1 trial that offering a self-sampling device for collecting cervico-vaginal 
lavage material for high-risk human papillomavirus (hrHPV) testing is a feasible and 
effective alternative for women not attending regular cytological screening, which 
improves coverage of the screening program significantly.(2;7) 
Here, we present data of the PROHTECT-2 study, in which we evaluated the 
performance of brush-based vaginal self-sampling for hrHPV testing among non-
attendees of the regular screening program. Outcome parameters were response rate, 
compliance to follow-up, concordance of hrHPV test results between vaginal self-
samples and physician-taken cervical scrapes, and yield of cervical intraepithelial 
neoplasia grade 2 or 3, or worse (CIN2+ or CIN3+) within 18 months of follow-up. 
 
Methods 
Trial design 
For PROHTECT-2, women were recruited who lived in the region Noord-Holland 
or Flevoland and, according to the database of the Regional Health Council, had not 
attended the organised cervical screening program in the year 2006 after the regular and 
reminder invitation. In that year, women who turned in their 30th, 35th, 40th, 45th, 50th, 55th 
or 60th birth year were invited for the regular program. Women were invited for 
PROHTECT-2 between November, 2007 and March, 2008.  
We randomised the women into a recall control arm and a self-sampling arm. 
The former did receive a second reminder invitation for regular cytology, while the latter 
received a self-sampling brush device (VibaBrush®, Rovers, Oss, The Netherlands) for 
hrHPV testing by the Hybrid Capture-2® method (HC2). Essentially the same trial design 
was used as for PROHTECT-1, in which HC2 test positive women were advised to visit 
a physician for a cervical scrape for cytology triage (see flowchart in Figure 1). All 
eligible women were sent a 1-week prior notice by surface mail to their home address to 
inform them about the study and alerting them on the possibility of either receiving a 
package for self-collection or a second re-invitation for regular cytology. After 1 week, 
women of the self-sampling group received a self-sample kit consisting of an explanatory 
letter with a brush for self-collection of a vaginal specimen, a collection vial containing 
1.5 mL universal collection medium (Qiagen, Gaithersburg, MD, USA), written and 
drawn instructions, an informed consent form and a return envelope. Women of the 
control recall group received an official second reminder to visit their physician for 
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regular cytology, an explanatory letter and an informed consent form. A website and 
telephone desk providing information of the study were available throughout the study 
period (http:// www.hpvthuistest.nl). 
We computed response rates in the recall control group and the self-sampling 
group and analysed in the self-sampling arm the CIN2+/CIN3+ yields within a period of 
18 months after receipt of the hrHPV test result. Analyses were done via record tracking 
of individual cases as well as via query from the nationwide network and registry of 
histology and cytology database (PALGA; Bunnik, the Netherlands). To verify the follow-
up data, the physician was contacted, if necessary. 
 
Randomisation 
To compare response rates, women were assigned to either a self-sampling 
group or a second re-invitation group for conventional cytology at a 99:1 ratio using 
computer‘s ‘randomize number generator‘. This skewed ratio was chosen to ensure 
adequate power to detect a difference in response rate between both study groups, but 
at the same time to maximize detection of CIN2+/CIN3+ rate among self-sampling 
responders.(7)  
The study was approved by the Ministry of Public Health (no. 2006/01WBO), and 
registered in the trial register (http://www.trialregister.nl/trialreg/admin 
/rctview.asp?TC=1851) as NTR1851. All participating women gave written informed 
consent. 
 
HPV testing of the self-sampled material  
Women of the self-sampling group were asked to send the collection vial 
containing the self-sampled vaginal specimen together with the signed informed consent 
to the laboratory for hrHPV testing at the department of pathology, VU University 
medical center, Amsterdam. After visual inspection of the liquid samples in the lab these 
were tested by HC2 according to the manufacturer‘s protocol, in an automated format on 
a rapid capture system (RCS) (6;10;11) This test uses a high-risk HPV cocktail probe, 
which is designed to detect HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 
68. Results of HC2 were expressed as relative light units per cut-off value (RLU/CO). 
When no clear cell material was visible in the samples beta-globin PCR was performed 
first (8). In case of a negative beta-globin PCR test samples were considered invalid for 
HC2 testing. In this case, women received a second self-sampling kit with the request to 
repeat self-sampling at home. 
 
Cytology reading 
Cervical smears were read in local laboratories and results were reported 
according to the CISOE-A classification, the standard classification system for cytology 
in The Netherlands, which can easily be translated into the Bethesda classification.(9) 
For this analysis, cytology results on the basis of either squamous- or columnar 
abnormalities were grouped as normal, borderline or mild dyskaryosis (BMD; 
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corresponding to Bethesda ASCUS/LSIL), or moderate dyskaryosis or worse (>BMD; 
corresponding to ASC-H/HSIL or worse). 
 
The follow-up triage of self-sampling group and control group 
All responding women in the self-sampling group received a written test result 
and explanation by mail. Those who were hrHPV-negative were advised to await the 
next screening round invitation (i.e., 5 years after 2006). All women who were hrHPV-
positive were advised to visit their physician for taking a scrape for cytology triage and 
blinded HPV testing. They were referred for colposcopy if the smear result was ≥BMD. In 
case of normal cytology they were re-invited after 1 year for a physician taken cervical 
scrape for cytology and hrHPV testing. Women with a positive cytology and/or hrHPV 
test result at that occasion were referred for colposcopy. In case a woman did not 
comply with the follow-up protocol at baseline or after 1 year, a reminder letter was sent 
to them with a copy to their physician. Women who had a double negative test result 
after 1 year, were advised to attend the next screening round.  
 Women responding in the recall control group received a cytology report of their 
physician-taken cervical specimen. Those with abnormal cytology were managed 
according to the guidelines of the national screening program (10;11). Endometrial 
abnormalities were excluded.  
 
Outcome measures 
The primary outcome measure of PROHTECT-2 was the response rate in both 
recall control and self-sampling arms. The time span for measuring attendance was 1 
year from the moment the study responders received either the recall invitation or self-
sampling device.  
The secondary outcome measures included the prevalence of hrHPV among 
self-sampling responders, adherence to cytology triage and referral, and the number of 
histologically confirmed CIN2+/CIN3+ within a follow-up period of 18 months. Women 
with normal cytology and a hrHPV-negative cervical sample were not referred for 
colposcopy, because their risk of CIN2+ was considered that low that the medical ethics 
committee found it unethical to refer these women for colposcopy. In the analyses these 
women were assumed to have no CIN2+.  
In addition, we assessed the concordance between hrHPV tests results on 
physician-taken smears versus self-sampled vaginal material of self-sample hrHPV-
positive women and evaluated the CIN2+/CIN3+ outcome according to either HPV test 
result.  
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Results 
 
Study cohort 
A flowchart of the study design is given in Figure 1. A total of 26,409 non-
attendees were eligible for inclusion in PROHTECT-2. After randomisation, 26,145 self-
sampling kits were sent to women registered as non-attendees, and 264 non-attendees 
received a second reminder for regular cytology screening. 584 women in the self-
sampling arm and 3 women in the control group did not respond to the study because 
they reported having had a hysterectomy or meanwhile passed away, leaving 25,561 
women in the self-sampling arm and 261 women in the recall control arm, respectively. 
No statistically significant differences were found between the age distributions in both 
arms.  
 
Figure 1: Study design for comparison of compliance rates between the recall 
control group and self- sampling group 
  
 
  
 
                     
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
 
            
Non-attendees of the regular screening programme in 2005-2006 
 
n = 26,409 
Randomisation 1:99 
Recall control group 
n = 264 
Self-sampling group 
n = 26,145 
Participation 
(conventional cytology at general 
practitioner 
n = 17 (6.5%) 
Non-eligible* 
n = 3 
Participation 
(HPV-test with HC2) 
n = 7,870 (30.8%) 
Non-eligible* 
n = 584 
Invalid test 
n = 26 
Valid HPV-tests 
n = 7,844 
n = 261 
n = 25,561 
See Figure 2 for follow-up algorithm * Excluded due to prior hysterectomy 
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Response rate 
Of the self-sampling group, 7,870 women (30.8%; 95% CI 30.2% - 31.4%) 
submitted a self-sampled specimen. The response rate in the recall control group for 
cervical cytology was 17 out of 261 (6.5%; 95% CI 9.0% - 14.4%). The difference in 
response rate between the two study arms was statistically significant (χ2 =71.77; 
p<0.01). In the self-sampling arm, young women (29-33 years) showed a significantly 
lower response rate than older women (χ2 for linear trend=10.65; p<0.01), whereas no 
differences in response rate were found between women in the age strata from 34 to 63 
years (χ2 for linear trend=0.63; p=0.43). 
 
hrHPV detection rate 
Of the women who submitted a self-sampled specimen, 26 (0.3%) had an invalid 
hrHPV test result, leaving 7,844 women with a valid test (99.7%) (Figure 1). Among the 
latter, 652 (8.3%; Table 1) had a positive hrHPV test result. The percentage of hrHPV-
positive women decreased with age from 15.6% in women of 29-33 years of age to 4.6% 
in women aged 59-63 years (χ2 for linear trend=113.14; p<0.01). The proportion of 
hrHPV-positive women did not decrease with age in women of 44 years and older (χ2 for 
linear trend=0.69; p=0.406).  
 
Compliance to follow-up of hrHPV-positive women in self-sampling group 
Seventy one of 652 (10.9%) hrHPV-positive women did not adhere to invitations 
for cytology triage testing, leaving 581 women (89.1%) with a cervical scrape taken by 
their physician. Of these, 28 women (4.8%) did not have a cervical smear, but only a 
hrHPV-test. Another 100 women (17.2%) had only a cytology result. The remaining 453 
women (78.0%) followed the protocol and had both cytology and hrHPV-test results.  
Of the 581 women with follow-up 192 (33.0%) had abnormal cytology (i.e. 
>BMD), of whom 184 (95.8%) adhered to the advice for direct referral to the 
gynaecologist for colposcopy. Another 8 women (4.2%) declined further follow-up (n=2), 
or did not comply to repeated advice for direct referral for colposcopy (n=6). 
Of the 389 women without cytological abnormalities (including 28 women who 
had only a hrHPV test) 226 (58.1%) adhered to the follow-up protocol of repeat testing 
after 1 year. Sixty nine women (41.9%) declined further follow-up, and 94 women did not 
adhere to repeated advice for repeat testing at 1 year (in total 163 women). Amongst the 
226 women with a repeat test after 1 year, 45 (19.9%) had cytological abnormalities 
and/or a hrHPV-positive test result. Twenty-seven (60.0%) of these women completed 
follow-up with histology (Figure 2).  
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Figure 2: Study design for evaluation of CIN2+ yield in women of the self-sampling 
group. 
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Cervical carcinoma, CIN3+ and CIN2+ yield among hrHPV-positive self-sampling 
responders 
Among 185 self-sampling responders with ≥BMD who visited a gynaecologist at 
baseline 7 cervical squamous cell carcinomas (3.6%), 68 CIN3 (35.4%), and 35 CIN2 
(18.2 %) lesions were detected. Most CIN2+ lesions were found in the youngest age 
group (29-33 years).  
Of the 27 women who underwent colposcopy after one year, 1 had cervical carcinoma 
(3.8%), 5 had CIN3 (18.5%) and 3 had CIN2 (11.1%). All of these 9 women had 
abnormal cytology and those tested for hrHPV (n=3) were hrHPV positive. At baseline 8 
of these 9 women had normal cytology and 1 had no cytology result. The 5 women with 
CIN3 and 1 woman with CIN2 had a hrHPV-positive physician-taken scrape, whereas 2 
remaining women with CIN2 had an invalid baseline hrHPV test on the physician-taken 
scrape. Strikingly, in the woman with cervical cancer the hrHPV test performed on the 
physician taken smear at baseline was negative.  
The cumulative 18-month CIN3+ and CIN2+ yields in women with a hrHPV-
positive self-sampling test were 1.0% (81 of 7,844) and 1.5% (119 of 7,844), respectively 
(see Table 1 and Figure 2). After stratification into age groups, the CIN2+/CIN3+ yields 
appeared significantly higher in young women (aged 29-33 years) compared to older 
women (aged 34-63 years; CIN2+: 3.6% vs 1.1%, respectively; p<0.001, and for CIN3+: 
2.7% vs 0.7%, respectively; p<0.001). Also, significant differences were found when 
comparing women aged 29-38 years to women of 39-63 years (CIN2+: 2.9% vs 0.8%, 
respectively; p<0.01; CIN3+: 2.0% vs 0.8%, respectively; p<0.01).  
 
 
hrHPV test results of physician-taken cervical scrapes versus self-samples in 
relation to histological outcome 
  In total 481 out of 652 (73.8%) women with a hrHPV-positive vaginal self-sample 
test also had a hrHPV-test performed on their physician-taken cervical scrape at 
baseline. The mean time interval between the self-sampling test result and that of the 
physician-taken scrape at baseline was 76 days (median: 58 days). Three smears 
(0.6%) had invalid hrHPV results, leaving 478 samples (99.4%) with a valid test result. 
The concordance between the hrHPV test result of physician-taken cervical scrape and 
vaginal self-sample was 68.8% (329 out of 478 women) (95% CI 64.7% to 73.0%; see 
Table 2).  
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Table 2: HPV test results on physician-taken cervical scrapes of 652 women with hrHPV-
positive self-samples in relation to histological outcome 
 
 < CIN 1 CIN 2 CIN 3 CxCa No hist fup Total 
HPV-positive 50 (80.6%) 27 (90.0%) 61 (96.8%) 3 (75.0%) 188 (58.9%) 329 (68.8%) 
HPV-negative 12 (19.4%) 3 (10.0%) 2 (3.2%) 1 (25.0%) 131 (41.1%) 149 (31.2%) 
Invalid HPV test* 0 2 - - 1 3 
No HPV-test performed** 13 6 10 4 138 171 
Total 75 (100%) 38 (100%) 73 (100%) 8 (100%) 458 (100%) 652 (100%) 
* Samples inadequate for HPV testing and **women without an HPV test on physician-taken 
cervical scrape are not included in the given percentages 
 
 
 
  The mean time interval between the self-sampling test result and that of the 
physician-taken scrape at baseline of the 329 women with an hrHPV positive physician 
sample was 68 days (range 6-332 days) with 28 women (8.5%) having their physician-
taken sample >4 months after the self-sampling result. In contrast for the 149 women 
with a hrHPV-negative physician-taken sample the mean time interval between the self-
sampling test result and the physician-taken scrape at baseline was 92 days (range 16-
337 days) with 38 women (25.5%) having their physician-taken scrape taken >4 months 
(p<0.001). This longer time interval in women with an hrHPV-negative physician-taken 
scrape suggest that these women have cleared their HPV infection in the time interval 
between self-sampling and the physician-taken scrape. In women with CIN2+ and CIN3+ 
the concordance rate in hrHPV-positivity between both samples was very high (CIN2+: 
91/97 (93.8%), and CIN3+: 64/67 (95.5%; see Table 2).  
The histological outcome in relation to the hrHPV test result on the physician-
taken scrapes in women with hrHPV positive self-samples at baseline is shown in Table 
2. Of the 8 women with carcinoma, 4 (50.0%) had a hrHPV-test performed on a 
physician-taken scrape, of which 3 (75.0%) were hrHPV-positive. This hrHPV-negative 
woman also had normal cytology at baseline and was detected by abnormal cytology 
after 1 year. Of the women with CIN3, 61 of 63 (96.8%) of the physician-taken scrapes 
were hrHPV-positive. Of the 30 cervical scrapes of women with CIN2, 27 (90.0%) were 
hrHPV-positive. 80.6% (50/62) of the physician-taken cervical scrapes of self-sample 
hrHPV-positive women with <CIN1, were hrHPV-positive as well. The remaining 188 
women with hrHPV positive physician-taken scrapes had no histology follow-up data. 
 
 
Discussion 
In this study, we showed that offering a brush for vaginal self-sampling to non-
attendees of the regular screening programme significantly increases the response rate 
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in the cervical screening programme compared to a repeat reminder for a physician-
taken scrape. Together with the high 18 month yield of CIN2+ (1.5%;119 of 7844) and 
CIN3+ (1.0%;81 of 7,844) obtained following hrHPV HC2 testing of these samples, this 
indicates that vaginal self-sampling using a brush is an attractive approach to increase 
the effectiveness of the cervical screening program, both in terms of response rate and 
high-grade lesion yield.  
The adherence of the responders with a positive hrHPV test to a cytology triage 
test was high (89.1%), and that to direct colposcopy referral after abnormal cytology 
even higher (95.8% at baseline). However, young (age 29-33 years) and older (age >53 
years) women with hrHPV-positive self-sampled material showed a lower adherence to 
cytology triage compared to women aged 34-53 years. Such an age difference was also 
observed in previous studies on attendance to screening programs.(1;5;12) We noticed 
that sending reminders to hrHPV-positive women and their physicians explaining the 
consequences of the test result increased the adherence to cytology triage at baseline. 
Janerich et al. also showed that the use of patient reminder systems for adherence to 
follow-up procedures can greatly reduce the number of women with a delayed diagnosis 
of CIN2+.(12) Conversely, loss to follow-up after a one year repeat testing advice of 
women without abnormal cytology at baseline was substantial (58.1% of these women 
complied after one year). A similar compliance with one year follow-up (i.e. 57.4%) was 
obtained in the PROHTECT-1 study.(7) Therefore, we expect that the yield of 
CIN2+/CIN3+ lesions detected in this study is still underestimated. The positive effect on 
compliance of sending reminders to women and their physicians strongly argue for 
adding this approach in a recall system of these women. 
Amongst all outcome measures analysed in this study only response rate in the 
self-sampling group and and hrHPV positivity differed slightly with those of PROHTECT-
1. The self-sampling response rate was slightly higher (30.5% vs 27.4%) and hrHPV 
positivity somewhat lower (8.3% vs 10.3%) in this study compared to PROHTECT-1. We 
do not have a good explanation for these findings. However, the total yield of CIN2+ and 
CIN3+ among participated women did not differ (PROHTECT-1: 99/7,384 (1.3%) and 
PROHTECT-2: 119/7,844 (1.5%) for CIN2+, and PROHTECT-1: 76/7,384 (1.0%) and 
PROHTECT-2: 81/7,844 (1.0%) for CIN3+). This indicates that for the detection of high-
grade CIN lesions and cervical carcinomas by hrHPV testing both self-sampling devices 
show good results. However, we noticed that the amount of cells collected by the brush 
self-sampler device is at least 3 times lower than obtained by the Delphi cervico-vaginal 
lavage self-sampler (data not shown). Together with the fact that brush samples 
primarily contain vaginal cells, this makes brush sampled material less suited for 
additional molecular tests for disease markers. 
The overall concordance between hrHPV-positive physician-taken scrapes and 
self-samples at baseline was 68.8%. The hrHPV-negative results on the physician-taken 
scrapes may in part be explained by the presence of vaginal HPV infections detectable 
by HC2 (7). In addition, 25.5% of women with a hrHPV-negative physician-collected 
sample visited their physician for a cervical scrape at least 4 months after self-sampling, 
and might have cleared the hrHPV infection in between. By comparison, only 8.5% 
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women with a hrHPV-positive physician-obtained sample waited >4 months to visit their 
physician for a cervical scrape. Importantly, the concordance between hrHPV test results 
on physician-taken scrapes and self-sampled vaginal material of women with high-grade 
CIN or cervical cancer, and consequently a persistent HPV infection, was very high 
(>95% for CIN3+).  
The strengths of this study are its large size and performance within the setting of 
the regular screening program. The data confirm those of the earlier study performed 
with a lavage self-sampler (PROHTECT-1) conducted in the same region.(7) In both 
studies, the response rate was approximately 30%, indicating that a similar proportion of 
non-attendees can be reached by offering hrHPV testing on self-sampled material 
collected by both devices. Even more important is that in both studies similar yields of 
high-grade CIN and cervical cancer were obtained.  
The poor adherence to follow-up testing after 1 year is a weakness of this study 
(58.1%), especially when compared to the high compliance rate at baseline (89.1%). As 
pointed out before, this has a likely negative effect on CIN2+/CIN3+ yields. Striking was 
that even women with abnormal cytology after 1 year showed a relatively poor 
adherence to referral for colposcopy (60.0% vs. 95.8% at baseline). Although we do not 
have an explanation for this finding, we had the impression that better education of the 
women as well as physicians about the possible screening results might help to improve 
the compliance to visit the physician after 1 year. 
Many studies, often performed on small numbers of women and with different 
self-sampling devices and hrHPV detection techniques have compared self- versus 
physician-sampling, though mostly at the level of HPV test performance rather than the 
yield of CIN2+/CIN3+.(13-16) Generally, a high level of concordance between the HPV 
test results on self- versus physician-taken samples was obtained.(13-14) As we have 
shown earlier offering HPV testing on self-sampled cervical material should not only be 
evaluated at the level of HPV test performance but also the level of CIN2+/CIN3+ 
yield.(16) In fact, the whole chain of self-sampling, HPV testing with a clinically validated 
test (17), follow-up of HPV-positive women and the CIN2+/CIN3+ yield of the referred 
women should be evaluated before self-sampling can be introduced in routine screening. 
Non-attendees of the regular screening program form an ideal group of women to test 
the performance of HPV self-sampling, not only because the prevalence of high-grade 
cervical lesions is higher than in women who participate in regular screening 
program(85), but also because there is no other effective alternative for non-attendees. 
Together, the results of both PROHTECT-1 and PROHTECT-2 are so 
encouraging that efforts are warranted to study offering self-sampling as a more 
pleasant alternative for a physician-taken smear to women (age 30-60 years) invited for 
regular screening programs.  
In summary, offering hrHPV testing on self-sampled vaginal material with a brush 
device to non-attendees of the regular screening program significantly increases the 
attendance to the regular screening program, results in HPV test results that are in good 
concordance with those on physician-taken scrapes in women with CIN2+/CIN3+ and is 
effective in detecting CIN2+/CIN3+.  
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Abstract 
 
Background Self-sampling for high-risk HPV (hrHPV) testing is accepted by up to 30% 
of non-attendees to the regular cervical screening programme. Here, the yield of CIN2 or 
worse (>CIN2) and CIN3 or worse (>CIN3) of 15,274 HPV self-sampling responders 
amongst non-attendees was compared to that of 176,027 women participating in regular 
screening in the same period and in the same region. We also analysed which 
subpopulations amongst non-attendees are targeted by HPV self-sampling, and which 
characteristics relate to hrHPV prevalence and yield of >CIN2/>CIN3. 
 
Method Data from two consecutive self-sampling studies were pooled. >CIN2/>CIN3 
yields, screening history, age and ethnic status were retrieved from centralized 
pathology and screening databases, respectively. A logistic regression model was fitted 
to analyze method of invitation, ethnicity, age group, and screening history as predictors 
for response rate, hrHPV presence and >CIN2/>CIN3 in non-attendees. For screening 
history analyses, women <34 years were excluded since it was the first screening round 
in their life. 
 
Findings ≥CIN2/≥CIN3 yields of HPV self-sampling responders were higher than those 
of screening participants (≥CIN2: relative risk (RR)=1.6, 95%CI=1.4-1.9; ≥CIN3: RR=1.8, 
95%CI=1.5-2.1 with relative risk values increasing with age (Test of Homogeneity: 
≥CIN2: p=0.04; ≥CIN3: p=0.03). 
Native Dutch non-attendees responded better than immigrants (32% versus 22%, 
p<0·001) and those screened in the previous round revealed a higher response than 
underscreened (i.e., previous smear taken >7 years ago) or never screened (34% 
versus 25%, p<0·001) women. Strikingly, amongst under- and never screened women 
aged >39 years, never screened women responded better (25% versus 23%, p<0·001). 
≥CIN2 rates were higher among responding native Dutch women than immigrants 
(p<0·01), and higher in under-/never screened women than in women screened in the 
previous round (p<0·01).  
 
Interpretation Offering hrHPV self-sampling increases the efficacy of the screening 
programme by targeting a substantial portion of non-attendees of all ethnic groups who 
have not regularly been screened and are at highest risk of ≥CIN2.  
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Introduction 
 
Organised cervical screening programmes have reduced the incidence of and mortality 
from cervical cancer.(1-3) Non- or infrequent attendance is one of the main threats to the 
success of those screening programmes.(4) Targeting non-attendees is important 
because these women have an increased risk of cervical cancer.(5) Recently, we found 
that offering self-sampling for high-risk HPV (hrHPV) testing (further referred to as HPV 
self-sampling) to non-attendees is an effective approach for increasing screening 
coverage (PROHTECT studies).(6;7)  
Nevertheless, it is still unknown which subpopulations of non-attendees, in terms of age, 
ethnicity and screening history, are targeted by HPV self-sampling. It is known that 
screening participation rates vary across ethnic populations.(8) Moreover, not being 
screened within previous screening intervals has been found to be associated with 
increased risks of cervical intraepithelial neoplasia (CIN) grades 2 and 3, and cervical 
cancer.(6;9-12)  
Here, we used the pooled data from the two consecutive PROHTECT HPV self-sampling 
studies comprising a total of 52,447 non-attendees of the regular screening programme 
recruited from 230,509 women invited for cervical screening in the counties Noord-
Holland and Flevoland in 2005 and 2006. First, we compared the yield of CIN2 or worse 
(>CIN2) and CIN3 or worse (>CIN3) of HPV self-sampling responders (n=15,274) with 
that of their counterparts participating in primary cytology-based screening (n=176,027). 
In addition, we analysed which subpopulations amongst non-attendees are targeted by 
HPV self-sampling, and how these characteristics relate to hrHPV prevalence and yield 
of >CIN2 and >CIN3.(6;7) 
 
 
Methods 
Study population 
Non-attendees of the regular screening programme 
All 54,482 women out of 230,509 invitees (aged 30-60 years) in the counties 
Noord-Holland and Flevoland who did not attend the cervical screening programme after 
two invitations in 2005 and 2006 were registered as screening non-attendees and were 
recruited to participate in the PROHTECT studies from December 2006 to March 
2008.(6;7) In these studies, the effect of offering self-sampling for hrHPV DNA testing by 
Hybrid Capture 2 (HC2) on response rate and cumulative 18-month ≥CIN2/≥CIN3 yield 
was evaluated. Response rate was compared with women who received a second 
reminder for conventional cytology (recall control group). Written informed consent was 
provided by all women. The studies were approved by the Ministry of Public Health (no. 
2006/01WBO) and registered as International Standard Randomized Controlled Trial, 
numbers ISRCTN45527158 (PROHTECT-1) and NTR1851 (PROHTECT-2). In the 
PROHTECT-1 study (non-attendees in 2005), self-sampling of a (cervico)vaginal specimen 
by a lavage-based device (Delphi®-Screener, Delphi-bioscience, The Netherlands) was 
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offered to 27,792 women (self-sampling group), and a second recall for conventional 
cytology was sent to another 281 women (recall control group).(6) In PROHTECT-2 (non-
attendees in 2006) a brush-based self-sampling device (VibaBrush®, Rovers Medical 
Devices, The Netherlands) was offered to 26,145 women, whereas 264 women received 
a second recall for cytology.(7) Further study details have been described 
before(6;13;14). Apart from the self-sampling method, both PROHTECT studies were 
essentially the same in design. Women with a hrHPV-positive self-sample were advised 
to visit a general practitioner for a cervical smear and referred for colposcopy in case of 
abnormal cytology (threshold borderline or mild dyskaryosis (BMD), equalling AGC/ASC-
US/ASC-H/LSIL). Those with normal cytology received a re-invitation for a cervical 
scrape after one year, and were referred for colposcopy if either hrHPV test result was 
positive or cytology was abnormal. Women of the recall control groups were managed 
according to the current cytology guidelines of the national screening programme.(15) 
For the purpose of this study data from these PROHTECT studies were pooled. 
 
Screening participants  
The pooled 18 month yields of >CIN2/>CIN3 in the HPV sampling group were 
compared with those of all women (n=176,027) who did participate in the regular 
screening programme in the same region and the same period. These women were 
managed according to the current cytology screening guidelines(15).  
Cytology and histology results of both the HPV sampling group and the screening 
participants were obtained by querying the nationwide, centralized network and registry 
of histology and cytology database (PALGA; Bunnik, the Netherlands(16)) as well as 
record tracking of individual cases of invited non-attendees. We linked patient records 
based on identity of the encrypted first four letters of the maiden name and date of birth. 
Groups of records presumably belonging to a single person were ‗eyeballed‘ (checking 
every case manually) to filter out administrative twins by checking domicile, initials, and 
apparent inconsistencies in clinical history. 
 
Study parameters  
Response rate in PROHTECT was operationally defined as the proportion of 
eligible women of both arms who sent in an informed consent form, combined with 
submission of a self-sampled specimen for women assigned to the self-sampling 
group.(6;7) hrHPV prevalence was defined as percentage of women with HC2 hrHPV-
positive self-sampled specimens.(6;7)  
Yields of ≥CIN2/≥CIN3/cervical carcinoma refer to the 18-month cumulative 
yields of these lesions in women in the self-sampling group who submitted a self-
collected specimen or women who participated in the screening programme.  
Ethnic status of non-attendees defined by country of birth was retrieved from the 
invitational database of the Regional Health Council. In accordance with the method of 
the Dutch Central Bureau of Statistics, countries of origin (in total, n=188) were grouped 
into three major groups: The Netherlands (native Dutch), Other Developed countries 
(i.e., Europe, USA/Canada, Australia, New-Zealand) and Developing countries (i.e., the 
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major 4 immigrant populations in the Netherlands (The Netherlands Antilles, Surinam, 
Turkey, Morocco) and Other Developing countries). 
In the Netherlands, women are invited for screening every five years in the year 
in which they reach the age of 30, 35, 40 etc. till 60 years. Age categorization was based 
on the number of prior screening rounds for which women had been invited. As a 
consequence the following age categories were defined: 29-33 years, 34-38 years, 39-
43 years, 44-48 years, 49-53 years, 54-58 years, and 59-63 years. 
For cytology screening history of non-attendees the time period between the 
invitation for HPV self-sampling and the last smear taken prior to the PROHTECT test was 
considered. For this subgroup comparison, only women who had been invited in one or 
more previous screening rounds (i.e., women aged 34-63 years; n=43,979) were 
included since younger women had no screening history. Since the PALGA database 
was linked with the invitational database for call and recall not earlier than in 2006, 
smears made for the invitational screening programme and opportunistic/diagnostic 
smears were similarly assigned. Based on time since the last smear, women were 
categorized into one of three subgroups: 1. last smear taken <7 years before 
participating to HPV self-sampling, considered to represent women screened in the 
previous round, 2. last smear taken >7 years ago (i.e., underscreened women) or 3. no 
smear in the past (i.e., never screened women). It should be noticed that PALGA has 
been virtually complete only since 1990 onwards (www.palga.nl). This means that the 
screening history can be screened only till 1990, and "no screening history in the past" is 
defined  as no screening history in the past approximately 15 years. 
 
Table 1: Characteristics of self-sampling groups of individual PROHTECT studies 
 
 
Data analysis 
The pooled 18-month cumulative ≥CIN2/≥CIN3 yields in self-sampling 
responders were compared with those of screening responders using Mantel-Haenszel 
(M-H) Chi-square testing. For analyzing the age stratified data we used the M-H test of 
homogeneity.  
 PROHTECT-1 PROHTECT-2 OR (95% CI) 
Year of non-attendance 2005 2006  
Year of recruitment for study 2006-2007 2007-2008  
Device  Delphi Screener Viba Brush   
Number of eligible women  26,886 25,561  
Response rate to HPV self-sampling 7,404 (27%) 7,870 (31%) 0·8 (0·8 - 0·9) 
hrHPV positivity amongst  
self-sampling responders 
757 (10·2%) 652 (8·3%) 1·3 (1·2 - 1·5) 
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We performed multiple logistic regression analyses models on the potential risk 
factors as ethnic background, age group, and screening history. Outcome measures 
were response to HPV self-sampling invitation, hrHPV test result, 
≥CIN2/≥CIN3/carcinoma. In the analyses for response to self-sampling invitation, the 
method of invitation (self-sampling or second recall) was also included as a predictor. 
Significance of the effects was evaluated with the Wald test. For all tests a significance 
level () of 0·05 was used. 
The analyses were performed by using SPSS 15·0 software and STATA 10·0 package). 
 
Results 
HPV self-sampling responders of non attendees of the regular screening 
programme 
In the PROHTECT studies, a total of 54,482 non-attendees were recruited, of 
whom 53,937 women were allocated to the self-sampling group and 545 to the recall 
control group. A total of 1,490 women were non-eligible, mainly due to previous 
hysterectomy, leaving 52,447 women in the self-sampling group. Seven women in the 
recall control group were non-eligible, leaving 538 women. Finally 15,274 women (29%) 
submitted a self-sampled specimen. Table 1 provides further details of the self-sampling 
groups of the individual PROHTECT studies. 
 
Comparison of ≥CIN2/≥CIN3 yields between self-sampling responders and 
screening participants  
Figure 1 and Table 2 show the pooled cumulative 18-month ≥CIN2/≥CIN3 yields 
in PROHTECT self-sampling responders versus screening participants. The ≥CIN2/≥CIN3 
yields of self-sampling responders were higher than those of screening participants 
(≥CIN2: relative risk (RR)=1·6, 95%CI=1·4-1·9; ≥CIN3: RR=1·8, 95%CI=1·5-2·1). These 
relative risk values increased with age (Test of Homogeneity (M-H): ≥CIN2: p=0·04; 
≥CIN3: p=0·03), but were also significantly higher than 1 in women aged 29–33 years 
(≥CIN2: RR=1·4, 95% CI=1·1-1·8; ≥CIN3: RR=1·6, 95% CI=1·2-2·2). When restricting 
the analysis to women who had abnormal cytology (≥BMD) at baseline similar relative 
risk values were obtained. In for example women aged 29–33 years with abnormal 
cytology these relative risks were 1·4 (95% CI=1·1-1·8) and 1·6 (95% CI=1·2-2·1) for 
≥CIN2 and ≥CIN3, respectively.  
Also cervical carcinomas were more frequently found among self-sampling 
responders than regular screening participants (0·09% vs 0·03%, p=0·002; Table 2). 
Due to the low number of carcinomas the effect of age could not be tested. 
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Figure 1: Yield of >cervical intraepithelial neoplasia (CIN)2 in pooled PROHTECT-1 
and PROHTECT-2 studies and amongst women participated the regular cervical 
screening programme. 
 
 
  
 
                  
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
 
Women invited for cytological screening in 2005-2006 
 
n = 230,509 
Non-attendees 
 
n = 54,482 
Screening participants 
 
n = 176,027 
HPV testing on self-
samples 
 
n = 15,274 (29%) 
Self-sampling arm 
 
n = 52,447 
Recall control 
arm 
n = 538 
Non-eligible* 
 
n = 1,497 
 
CIN2             n = 61 (0.4%) 
CIN3             n = 144 (0.9%) 
Carcinoma   n = 13 (0.09%) 
Histology after 18 months  
 
CIN2              n = 540 (0.3%) 
CIN3              n = 941 (0.5%) 
Carcinoma    n = 59 (0.03%) 
Histology after 18 months  
* Excluded due to prior hysterectomy or past away during the study 
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Response rate of non-attendees in relation to invitational method, ethnicity, age, 
and screening history 
The response rate was analyzed by fitting a logistic regression model with 
method of invitation, ethnicity, age group, and screening history as predictors.  
Women assigned to the self-sampling group responded significantly better than those 
assigned to the recall control group (29% versus 12%; χ2(1)=73.9, p<0·001, OR=3.2, 
95% CI= 2.5-4.2; Table 2). The response rate was also related to ethnicity (χ2(6)= 595.5, 
p<0·001), age (χ2(6)=26.6, p<0·001), and screening history in women ≥34 years 
(χ2(2)=429.4, p<0·001). 
Native Dutch women responded better than immigrant women (χ2(1)=402·6, 
p<0·001, OR=24, 95% CI=18-33), and of the immigrants, those from Other Developed 
countries revealed a higher response rate than those from Developing countries 
(χ2(1)=8·6, p<0·01, OR=2·0, 95% CI=1·3-3·1). No differences in response rate between 
subgroups of immigrants from Developing countries (i.e., Netherlands Antilles, Surinam, 
Turkey, and Morocco versus Other Developing countries) were found (Table 3).  
There was no age trend in the response rate among PROHTECT-women (Table 4).  
Amongst women of ≥34 years, those who were screened at the previous 
screening round revealed a higher response rate (7,259/21,185; 34%) than 
underscreened or never screened women (5,733/23,240; 25%; χ2(1)=389·4, p<0·001, 
OR=1·5, 95% CI=1·5-1·6). This difference was also evident when the analysis was 
restricted to women ≥39 years, who had been invited at least two prior screening rounds 
(χ2(1)=420·9, p<0·001, OR=2·7, 95% CI=2·5-3·0). Strikingly, amongst women ≥39 
years, never screened women revealed a higher response rate (2,270/9,151; 25%) than 
underscreened women (2,039/9,024; 23%; χ2(1)=33·3, p<0·001, OR=1·2, 95% CI=1·2-
1·3). This was evident for women of all ethnic groups, although for immigrant women 
from Other Developing countries this difference did not reach significance (Figure 2). 
 
HPV prevalence in relation to ethnicity, age, and screening history 
Of the 15,274 women who submitted a self-sampled specimen, 1,409 (9·2%) 
were hrHPV-positive. Neither ethnicity (χ2(6)=7·4, p=0·3) nor screening history (women 
≥34 years: χ2(2)=0·2, p=0·9) were found to be related to hrHPV prevalence. The 
proportion of hrHPV-positive women decreased with age till the age category 39-43 
years (29–33 years: 15% (χ2(1)=129·8, p<0·001), 34–38 years: 11·7% (χ2(1)=70·8, 
 104 
p<0·001), 39–43 years: 8·1% (χ2(1)=7·0, p<0·01, OR=1·3, 95% CI=1·1-1·5), and 
remained stable in older women (Table 4).  
 
≥CIN2/≥CIN3 yield in relation to ethnicity, age, and screening history 
Sixty one (0·4%) of the self-sampling responders had CIN2, 144 (0·9%) CIN3, 
and 13 (0·09%) cervical carcinoma (Figure 1). The overall ≥CIN2 and ≥CIN3 yields were 
1·4% (n=218) and 1·0% (n=157), respectively (Table 3).  
Both the ≥CIN2 and ≥CIN3 rates were related to ethnicity (≥CIN2: χ2(2)=14·6, 
p<0·001; ≥CIN3: χ2 (2)=9·2, p<0·01). The ≥CIN2/≥CIN3 rates were higher among native 
Dutch women than among immigrants (≥CIN2: χ2(1)=13·0, p<0·01, OR=2·4, 95% 
CI=1·5-3·8; ≥CIN3: χ2(1)=8·7, p<0·01, OR=2·6, 95% CI=1·4-4·9). No significant 
difference was found between immigrant women from Developed countries and those 
from Developing countries. Due to the low frequencies of ≥CIN2 no further subdivision 
was made among women from Developing countries. 
 
The ≥CIN2/ ≥CIN3 yields were significantly related to age (≥CIN2: χ2(6)=52·3, 
p<0·001; ≥CIN3: χ2(6)=38·4, p<0·001) and were relatively high in young women. Of all 
≥CIN2 lesions, 32% were in the group of 29-33 years and only 3·2% were in the group of 
59-63 years; likewise 34% of all ≥CIN3 were in the group of 29-33 years and 3·8% in 
women of 59-63 years.  
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The effect of screening history of women ≥34 years on ≥CIN2/≥CIN3/carcinoma 
yields, stratified by ethnicity and age, is shown in Table 5. There was a significant effect 
of screening history on both ≥CIN2 (χ2(2)=11·1, p<0·01) and ≥CIN3 (χ2(2)=6·6, p<0·05). 
Women who were under- or never screened revealed significantly higher ≥CIN2/≥CIN3 
yields than women screened within the last 7 years (≥CIN2: χ2 (1)=7·8, p<0·01, OR=2·7, 
95% CI=1·3-5·3) and ≥CIN3: χ2(1)=4·6, p<0·05, OR=2·5, 95% CI=1·1-5·5). A similar 
effect was seen after restricting the analyses to women ≥39 years (≥CIN2: χ2(2)=14·2, 
p<0·001); ≥CIN3: χ2(2)=11·4, p<0·01). The ≥CIN2/≥CIN3 yields were highest in never 
screened women (Figure 3).  
Both in women of ≥34 and those of ≥39 years there was no significant effect of 
screening history on carcinoma yield. This reflects the fact that two carcinomas were 
diagnosed in women <33 years and the number of carcinomas in the older age groups 
was apparently too low to reach significance.  
 
 
Discussion  
In the screening region of the Netherlands investigated here the attendance rate 
was 67%, which is in agreement with the overall attendance in the Netherlands after one 
year. (65%)(17) Together with opportunistic smears the coverage of the population after 
5 years is about 77%(17-19), which leaves 23% invited women unprotected. We showed 
that the yields of ≥CIN2/≥CIN3 were higher in the HPV self-sampling group of the non-
attendees than in the regular attendees of the screening programme. Moreover, the 
relative ≥CIN2/≥CIN3 risk values increased with age.  
In addition, we found that Dutch non-attendees responded better and also 
revealed significantly higher ≥CIN2/≥CIN3 yields than their immigrant counterparts. 
Amongst women invited at earlier screening rounds, never screened women responded 
better to HPV self-sampling than underscreened women, independent from ethnicity. 
These underscreened and never screened women displayed the highest risk of 
≥CIN2/≥CIN3/carcinoma. These are the women who health programme managers 
particularly like to target to improve cervical cancer prevention strategies, supporting the 
notion that offering HPV self-sampling is a meaningful and effective approach for 
reaching those women who are in the highest need for cervical screening. Since non-
attendees harbour more than 50% of cervical cancers(9;12), targeting of approximately 
30% of these women by HPV self-sampling is likely to result in earlier detection of at 
least 15% of the cervical carcinomas. 
For this study, we pooled data from two large self-sampling studies. Independent 
from ethnicity, age, and screening history, we measured different response rates 
between the individual PROHTECT studies. In PROHTECT-1 slightly fewer women 
responded than in PROHTECT-2 (27% vs 31%). This small difference may partly reflect a 
higher acceptability of the brush device used in PROHTECT-2 compared to the lavage-
device used in PROHTECT-1. Alternatively, since PROHTECT-1 was performed prior to 
PROHTECT-2, the difference might be attributable to more awareness, and therefore less 
uncertainty, due to the earlier publicity around the PROHTECT-1 study.  
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Most interesting is the finding that never screened women were more likely to respond 
than underscreened women, independent from the ethnic background. Although it is still 
unclear why never screened women responded better than underscreened women, a 
plausible explanation might be that these women consistently refuse to visit the 
physician for making a preventive smear because of cultural, religious and/or 
organisational reasons. HPV self-sampling may help to overcome this barrier.  
It should be realized that increased ≥CIN2/≥CIN3 yield in self-sampling responders 
might be the result of a more sensitive screening test (hrHPV test used in self-sampling 
compared to the cytology test used for screening participants). However, similar relative 
risk values were obtained after restricting the analysis to women with abnormal cytology 
at baseline. Therefore, the increased relative risk of self-sampling responders cannot 
solely be attributed to a more sensitive screening test.  
An unexpected observation was that an increased relative risk of ≥CIN2/≥CIN3 was also 
found among self-sampling responders for whom it was their first screening round. A 
likely explanation for this finding is that women at risk because of their lifestyle (e.g. in 
terms of sexual behaviour and smoking habits) are better targeted by offering HPV self-
sampling than by invitation for a physician-collected cervical scrape. The increased 
relative risks by age most likely reflect an overall poorer screening history of older self-
sampling responders.  
Our study is unique, because of its large size and performance within the setting of the 
regular cervical screening programme. Moreover characteristics of non-attendees of the 
screening programme who responded to self-sampling for HPV testing has not been 
described before. A limitation is that we pooled two studies in which different collection 
devices were used. As reported earlier(7), hrHPV-positivity rates slightly differed 
between samples collected by both devices, but the concordance between hrHPV-
positivity rates in both types of self-collected samples and corresponding physician-
collected cervical samples was very high (over 90%) in women with ≥CIN2.(6;21) 
Furthermore, >CIN2 yield was comparable in both studies(7) indicating that it is unlikely 
that pooling the PROHTECT studies would influence the interpretation of the results.  
Another limitation is that we did not test the prevalence of ≥CIN2 in women with hrHPV-
negative self-sample test. The medical ethics committee considered follow-up of these 
women in light of the very high negative predictive value of the hrHPV test for ≥CIN2 an 
unnecessary burden.(22)  
Finally we defined ethnic status based on the country of birth. Thus some women from 
ethnic minorities who were born in the Netherlands might have been classified as "native 
Dutch", even though culturally they may to some degree resemble paternal immigrant 
communities. Although this might play a role predominantly among younger women we 
think that the number of women concerned is limited. Most women who united with their 
husband by immigration in The Netherlands did so in the late late 1970‘s, begin 1980‘s. 
The number of women born from these immigrated women and invited for screening (30-
60 years) constitutes in our opinion therefore a small minority   
Finally, it is important to note that in order to make HPV self-sampling a successful 
alternative to physician-sampling, the whole organisation should be well controlled. This 
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involves the sequence of sending the invitation with the self-sampling kit, return sending 
by surface mail, hrHPV testing with a clinically validated test that is compatible with the 
self-sampling device, follow-up of hrHPV-positive women by triage cytology by a 
physician and follow-up of hrHPV-positive women with normal cytology after 6 months to 
1 year. We showed earlier that compliance to direct cytology triage is high (≥90%) but 
that there is poor adherence to follow-up testing after 1 year (~60%), which needs 
careful attention.(6;7) Still, these results strongly argue to implement hrHPV testing on 
self-sampled material as an alternative for hrHPV testing on a physician taken scrape.  
 
Conclusion 
Amongst women who had not been screened in the previous screening round, those 
who were never screened before were preferentially attained when offering HPV self-
sampling. This likely contributed to higher ≥CIN2/≥CIN3 yields than found in regular 
screening participants, which is highly relevant for the success of the screening 
programme. Although native Dutch women responded better than immigrants, the 
response rates among immigrants from different countries hardly differed, making the 
method successful independent from country of birth.  
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Abstract 
 
Objective Addition of high-risk human papillomavirus (hrHPV) testing to post-treatment 
monitoring policies of women treated for high-grade cervical intraepithelial neoplasia 
(CIN) may improve the effectiveness of detecting recurrent/residual disease. Recent 
studies have shown that HPV type 16 confers an increased risk of high-grade CIN and 
cervical cancer.  This study aimed to find out whether the post-treatment CIN 3 rate is 
increased in HPV 16 positive women treated for CIN 3.  
 
Methods We included 229 hrHPV positive women treated for CIN 3. HPV typing was 
performed by GP5+/6+-PCR followed by reverse line blotting on a cervical scrape taken 
before treatment. HPV typing data were related to the occurrence of post-treatment CIN 
3 within a median follow-up time of 20.1 months (range 3-85.4 months) following 
treatment. 
 
Results Twenty nine of the 151 (19%) HPV 16 positive women versus 6 of the 78 (8%) 
women with other hrHPV types had recurrent/residual  CIN 3. Post-treatment CIN 3 rate 
was significantly increased in women with HPV 16 compared to those harbouring other 
hrHPV types (p=0.03). None of the other hrHPV types were associated with higher post-
treatment CIN 3 rates. 
 
Conclusion Women treated for HPV 16 containing CIN 3 should be monitored more 
intensively because of their increased risk of post-treatment CIN 3. Thus, the HPV 
genotype should be considered in post-treatment monitoring policies.  
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Introduction 
Women  treated  for  high-grade  cervical  intraepithelial neoplasia (CIN  2/3)  
are  traditionally followed  for  at  least 2 years by cytology to check for recurrent or 
residual disease. Post-treatment CIN rates of 5-15% have been observed [1]. For the  
development,  maintenance,  and  progression  of  CIN  2/3 lesions, a persistent infection 
with high-risk human papillomavirus (hrHPV) is required [2,3]. Moreover, radical removal 
of CIN 2/3 lesions is associated with negative HPV test results in cervical smears [4]. 
Consequently, addition of hrHPV testing to post-treatment monitoring policies improves 
the effectiveness of detecting recurrent/residual disease [5-9]. 
Recent data indicate that among the hrHPV types, HPV16 confers by far the 
highest risk of high-grade CIN lesions and cervical cancer [10-12]. This raises the 
question whether there also exists an increased risk of post-treatment CIN in case of 
HPV16  infections compared to infections with other hrHPV types. In this study, we 
tested the hypothesis that an HPV16 infection  in  a  primary  CIN3  lesion  increases  the  
risk  of  a recurrent/residual CIN3 after treatment. 
 
 
Patients and methods 
 We used clinical follow-up and hrHPV typing data collected during the course of 
two studies [6,13], involving in total 332 women that were treated for CIN2/3. For the 
purpose of this study these data were pooled since the same method  of  hrHPV  testing  
was  performed  within  a  single  laboratory  under guidance  by  the  same  
investigators (departments  of Gynaecology  and Pathology,  VU  University  Medical  
Center,  Amsterdam).  The  mean  age  at baseline  (time of treatment) was  35  years  
(range  21-64  years). The median follow-up time was 20.1 months (range: 3.0-85.4 
months).  
Standard  follow-up  in  The  Netherlands  consists  of  repeat  smears  with 
cytological examination at  6,  12  and  24  months. Cervical smears were read according 
to the CISOE-A classification, and interpreted as normal, borderline dyskaryosis  (BMD), 
mild dyskaryosis, moderate dyskaryosis, severe dyskaryosis, suspected of carcinoma in 
situ, or suspected of carcinoma. Translation of this classification system into the Bethesda 
2001 classification has recently been described [14].  
For the purpose of the abovementioned studies, extra repeat smears were taken at  3  
and  18  months and, in addition to cytology, hrHPV testing was performed for 14 
hrHPV types (i.e., HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,59,66 and 68) by HPV 
consensus GP 5+/6+-PCR EIA followed by typing using reverse line blot analysis of PCR 
products [15].  
According  to  guidelines  currently  in  practice  in  The  Netherlands, 
colposcopic  examination  including  sampling  for  histological  verification  of suspect 
lesions was performed in case of a cytology reading of mild dyskaryosis or worse. Follow-
up ended after treatment for recurrent/residual disease. Time to recurrence/residue was 
measured in days. 
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Statistical analyses 
We selected women treated for CIN3 and compared the post-treatment CIN3 rate 
for those with HPV16 at baseline to that of women with other hrHPV types at baseline. In 
addition, the post-treatment CIN3 rate of women with HPV 18 was compared to those 
harboring hrHPV types different from both HPV16 and 18. HPV16 infections combined 
with other hrHPV types were considered as HPV16 multiple infections. Estimates of post-
treatment CIN3 rates were based on Kaplan-Meier survival analyses to correct for loss to 
follow-up. Testing for differences between the Kaplan-Meier curves was done with the 
log rank test. Crude estimates of the post-treatment CIN3 rates are given as well. We 
carried out the analyses both for single infections and multiple infections combined and for 
single infections only. 
 
 
Table 1: Type-specific post-treatment CIN 3 rates for women with a primary hrHPV positive 
CIN 3 lesion. Both women with multiple and single infections combined and women with 
single infections solely are shown. 
* HPV 16 is excluded from this comparison 
† Adjusted for loss to follow-up with Kaplan-Meier analysis 
‡ Based on the log rank test 
 
 
Of the 332 women, 229 had a hrHPV-positive CIN3 lesion at baseline (time of 
treatment). The remaining 103 women either had a hrHPV-positive CIN 2 lesion at 
baseline (83 women) or were hrHPV negative  (20  women). Table  1  shows the type-
specific  post-treatment  CIN3 rates,  both  for  women  with multiple and single hrHPV 
infections combined, and women with  a  single  infection  solely.  Of  the 229  hrHPV-
positive women with CIN3, 151 (66%) contained HPV16, of which 16 (11%) were 
infected with one or more other hrHPV types as well.  The  latter  included 3  women  
with  HPV16/18  double infections. Another 17 women had HPV 18, 5 (29%) of which 
involved multiple infections with types different from HPV16. The remaining 61 women 
were infected with hrHPV types other than  HPV16  and  18.  In  this  group  9  (15%)  
women  had  a multiple infection. 
hrHPV type Total N Crude estimates of the 
recurrence rate (%) 
Adjusted estimates of the 
recurrence rate (%)† 
p-value‡ 
Multiple and single infections    
16 vs other hrHPV 151 vs 78 19  vs 8 25 vs 8 0.03 
18 vs other hrHPV* 17 vs 61 0 vs 10 0 vs 10 0.19 
Single infections     
16 vs other hrHPV 
18 vs other hrHPV* 
135 vs 64 
12 vs 52 
20 vs 8 
0 vs 10 
26 vs 8 
0 vs 10 
0.04 
0.29 
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Crude post-treatment CIN3 rates were 19% (29 of 151) and 8%  (6  of  78)  for  
women  with  HPV16  single  and  multiple infections  combined  and  other  hrHPV  types,  
respectively. These figures did not change markedly when considering only multiple  
infections  with  and  without  HPV16.  Crude  post-treatment CIN3 rates were 13% (2 of 
16) versus 7% (1 of 14) for women with multiple infections containing HPV16 versus those 
having multiple infections with types different from HPV16. Post-treatment CIN3 rates 
adjusted for lost to follow-up were 25% (HPV16 single and multiple infections combined) 
and 8% (other  hrHPV  types).  These  differences  were  statistically significant (p = 
0.03).  None  of  the  20  women  in  which  no hrHPV was detectable revealed post-
treatment CIN3.  
  
Figure 1: Cumulative recurrence of CIN 3 after treatment for hrHPV positive CIN3 for 
women with HPV 16 versus other hrHPV types at baseline. Only single infections are 
included. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 When taking into account women with primary CIN 2 and CIN3 lesions and focusing on 
the combined post-treatment CIN 2 and CIN3 rates similar results were obtained, i.e., a 
significant difference in post-treatment CIN 2/3 rate between women with HPV16 
compared to those with other hrHPV types when single and  multiple  infections  were  
considered  together (data  not shown). 
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After  excluding  the 151  women  with  HPV16,  no  post-treatment CIN3 was 
observed in the 17 women with HPV 18 at baseline (crude estimate 0%, corrected estimate 
0%), whereas 6 of the remaining  61  women displayed CIN3  after treatment (crude 
estimate 10%, corrected estimate 10%). This difference, however, was not statistically 
significant (p = 0.19).  
The corresponding Kaplan-Meier curves for women with single HPV16  
infections versus those with single infections with other hrHPV types are shown in Fig. 
1. Twenty seven of the 135 HPV16 single infected women (20%) versus 5 of the 64 (8%) 
women having a single infection with a different type presented with a post-treatment 
CIN3. Single infections with HPV16  infections revealed a significantly increased 
adjusted post-treatment CIN3 rate (26% versus 8%; p = 0.04). 
 
 
Discussion  
We have shown that the post-treatment CIN3 rate in women containing  HPV16  at  
the  time  of treatment  is  significantly higher than in women with other hrHPV types. Our 
results are in line with  recent  findings  that  HPV16 exhibits  a  lower clearance rate than 
other hrHPV types [16,17] and an increased CIN 2/3 risk [10-12,18]. Moreover, HPV16 
accounts for the majority of hrHPV infections in HPV containing carcinomas of sites 
different from the uterine cervix [19]. All these findings suggest that HPV16 is more 
oncogenic than other hrHPV types.  
Previous studies have addressed the value of hrHPV testing in  addition  to  
cytology  in  detecting  recurrent  or  persistent lesions after treatment for primary CIN 
(reviewed by Zielinski et al. [20] and Arbyn et al. [5]). The results of our study indicate that  
there  is  also  a  potential  value  for  hrHPV  genotyping. Despite  the  relatively  small  
numbers  of  patients  in  this retrospective study, our data suggest that women with a 
primary lesion  containing  HPV16 should  be  monitored  with  more intensive awareness 
after treatment, given their increased risk of recurrent/residual disease. In this context a 
possible algorithm could be a 6-month follow-up of HPV16-positive women not only  by  
cytology,  as  is  currently  the  standard,  but  also  by hrHPV typing. In case the follow-up 
smear is HPV16-positive a colposcopical examination should be advised, irrespective of 
the  cytological  outcome. Larger  prospective  studies are warranted  to  investigate  
the  efficacy  of  such  an  alternative post-treatment  management  of  women  treated  
for  HPV16 containing high-grade CIN. 
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Literature data indicate that a substantial number of cervical carcinomas 
diagnosed in countries with a running, organised cervical screening programme is found 
in women who have not responded to an invitation for cervical screening.(1;2) Targeting 
these non-attending women is therefore of utmost importance to reduce the incidence of 
and mortality from this disease.  
In this thesis we firstly evaluated the screening history of women with cervical 
cancer in the Netherlands in order to get a better insight into this problem in relation to 
age and FIGO stage. In addition, this thesis reports on the results of implementing 
hrHPV testing on self-sampled (cervico)-vaginal material from non-attendees of the 
cervical screening programme. Response rates, hrHPV prevalence, compliance to 
follow-up, referral to physician and treatment, and yield of high-grade CIN and cervical 
carcinoma were investigated in relation to age, ethnicity and screening history. 
 
In Chapter 2, the adherence to the screening programme of women with cervical 
carcinoma was analysed in relation, age and FIGO stage of cervical cancer. We found 
that little more than half of the women with histologically-confirmed cervical carcinoma 
who were eligible for invitation for the screening programme were not screened in the 
last screening round, thus demonstrating that women with cervical cancer are still 
underscreened. Moreover, being underscreened or unscreened significantly correlated 
with higher cervical cancer stages, especially in older women. Advanced carcinoma or 
FIGO stage >2B occurred in 48.7% of poorly screened women as compared to 16.0% of 
screened women (p<0.001). Our results were in line with other studies in different 
settings and different populations.(1;3) Finally, in those women that were screened, we 
noted poor timeliness with respect to follow-up/referral strategies. Therefore, ways to 
increase adherence to screening and to optimise organisation aspects of the screening 
programme are important to improve the effectiveness of the screening programme. 
 
 In the Netherlands, several possibilities have been investigated to improve the 
attendance rate to screening, such as inviting women by their own GPs rather than 
health authorities(4;5), increased computerized support to practices and delegation of 
tasks to nurse practitioners.(6) However, the effect on attendance of these strategies is 
limited. A substantial proportion of women is still unwilling to visit their physician for 
making a cervical smear. Reasons for this include embarrassment, language and 
cultural difficulties with immigrant groups, time impediments for working women and 
improper individual risk assessment.(7)  
Previous studies from our group have shown that offering a self-sampling device 
for collecting cervico-vaginal material for hrHPV testing may improve the participating 
rate.(8-12) A Dutch pilot study showed that by offering a self-sampling device, 34% of 
non-attendees are willing to participate to screening, compared to 17% of women who 
received a second reminder for regular screening.(9) Moreover, this pilot showed that 
the yield of high-grade CIN and cervical cancer (CIN2+) was higher in self-sampling 
responders compared to screening participants (1.67 vs. 0.97%), suggesting hrHPV 
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testing on self-sampled cervico-vaginal specimens to be an effective alternative to 
protect non-attendees in the cervical screening programme. 
 
In Chapters 3 and 4, we continued the evaluation of offering self-sampling for 
hrHPV testing to non-responders of the regular cervical screening programme in a large, 
population-based screening setting (i.e. regions Noord-Holland and Flevoland of the 
Netherlands). The studies were entitled PROHTECT (PRotection by Offering HPV TEsting 
on Cervico-vaginal specimens Trial) 1 and 2. The first study evaluated a lavage device 
as self-sampling method (Figure 1a as used in PROHTECT-1 study, and Figure 1b shows 
an updated version), and in the second study a brush was offered (Figure 2). Main 
outcome measures were the response rate in comparison with sending a screening 
reminder invitation and yield of CIN2+/CIN3+. In addition, the concordance of HPV-test 
results between material sampled by the general practitioner and self-sampled cervico-
vaginal material was determined. 
Both studies showed that response rate in the self-sampling group was 
significantly higher than in the control group that received a recall for regular cytology 
screening (PROHTECT-1: 27.5%, and PROHTECT-2: 30.8%; p<0.001 in both studies). The 
yield of CIN2+ and CIN3+ lesions in self-sampling responders did not differ between 
both studies (i.e. 1.3% and 1.0%, respectively, in the first study, and 1.5% and 1.0%, 
respectively, in the second study. The overall concordance of HPV-test results between 
the GP-taken smear and the self-sampled specimen was 58.7% and 68.8% in 
PROHTECT-1 and PROHTECT-2, respectively. However, in women with CIN2+ and CIN3+, 
very high concordance figures were obtained (93.8% and 95.5%, respectively). 
Together, these data indicate that offering self-sampling for hrHPV testing is a much 
better alternative for women not attending the screening programme than sending them 
a second screening reminder letter. 
 
In Chapter 5 we present the overall results of pooled analyses of both PROHTECT 
studies with special emphasis on ethnicity, age, and screening history. Although the self-
sampling response rate was higher in native Dutch women than in immigrants (32.4% 
versus 21.8%, p<0.01) no marked differences were found between immigrants born in 
non-developed countries (21.1%) compared to those of developed countries (24.0%). 
Thus, the lower response rate amongst immigrants can not simply be attributed to 
differences in ethnicity. Moreover, the response rate was independent of age. In self-
sampling responders, who had not participated in the previous round of screening, 
increased rates of CIN2+/CIN3+/cervical carcinoma were found compared to women 
who had been screened in the last invitation round.(1.4%, 1.0%, 0.2% versus 0.9%, 
0.6%, 0.03%, respectively). These rates were even higher in never screened women 
and were independent from ethnicity. Thus screening history appeared the main 
determinant for risk of high-grade CIN and cervical cancer. These results indicate that 
offering self-sampling is a feasible and effective method to protect non-attendees of 
cervical screening, irrespective of their ethnic background, and that the highest benefit of 
this approach can be expected for underscreened and unscreened women.  
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Overall, data from this thesis revealed that offering self-sampling for HPV testing 
to non-attendees in cervical screening, would increase the coverage by at least 5.2%. 
The yield of CIN2+/CIN3+ and carcinoma, found in both PROHTECT cohort studies, was 
significantly higher than the yield of CIN2+/CIN3+ and carcinoma among women with a 
smear in the last invitation round. Therefore, we can conclude that the results of the 
PROHTECT studies strongly support the implementation of this method for women not 
attending the regular screening programme.  
 
 The effect of the screening programme is, however, also dependent on the 
follow-up strategies, for instance for women diagnosed with high-grade CIN. Recent 
studies have shown that HPV type 16 confers an increased risk of high-grade CIN and 
cervical cancer.(13-15) Therefore, addition of hrHPV testing and genotyping to post-
treatment monitoring policies of women treated for high-grade CIN may improve the 
effectiveness of detecting recurrent/residual disease. In Chapter 6, we studied whether 
the post-treatment CIN3 rate is increased in HPV16-positive women treated for CIN3. 
HPV typing was performed on a cervical scrape taken before treatment using the 
GP5+/6+-PCR method followed by reverse line blot assay. The results showed that post-
treatment CIN3 rate was significantly increased in women with HPV16 compared to 
those harbouring other hrHPV types (p=0.03). None of the other hrHPV types were 
associated with higher post-treatment CIN3 rates. For this reason, we advise that 
women treated for CIN3 lesions, with HPV16 as underlying cause, should be monitored 
more intensively because of their increased risk of post-treatment CIN3.  
 
Discussion and future perspectives 
 
 For years cervical scrapes taken by health professionals did constitute the basis 
for preparing conventional smears or liquid based cytology samples for cervical cancer 
screening. During the last years several efforts have been made to evaluate whether 
self-collected (cervico-)vaginal material could serve as a good alternative for physician-
collected cervical scrapes. Dacron- or cotton swabs, brushes and tampons or various 
lavage devices have been used as collection devices. Data from others and us have 
shown that offering self-sampling can improve screening attendance in developed 
countries (9;16;17)and facilitate access to cervical screening in developing regions 
possible.(18;19) In addition, interview surveys in which participants were asked for 
collection preference have shown that women prefer self- collection over physician-
collection.(20-23) Time and place of sampling, privacy and ease of sampling have been 
mentioned as advantages of self-sampling. Thus, there is a basis for self-sampling of 
vaginal- or cervico-vaginal specimens in cervical cancer screening. 
However, self-collected vaginal samples are not suited for accurate cytological 
assessment, because of lower specimen quality (low cellularity)(24) poor concordance 
with cytology on conventional smears taken by a physician(25;26) and much lower 
sensitivities for high-grade cervical disease.  
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Many studies have therefore focused on the use of self-samplers for HPV 
analysis.(22;27) Collectively, these studies have shown that self-sampling can be as 
efficient as physician-sampling in detecting hrHPV. Discordance in hrHPV detection 
rates between self- versus physician-collected samples, as has been reported in some 
studies, most likely reflect the use of different types of self-sampling devices (swap, 
brush, tampon or lavage) that will influence the cell yield, as well as different hrHPV 
detection methods that all have their specific features in terms of analytical sensitivity 
and specificity for hrHPV detection. Most importantly, however, is knowledge about the 
performance of hrHPV self-sampling with regard to disease outcome.  
Studies that have compared hrHPV testing on self-samples with cytology on 
physician-obtained cervical samples have shown that hrHPV testing on self-samplers is 
as sensitive or more sensitive for CIN2+ than cytology on physician-obtained cervical 
samplers.(25;28-33) Thus, hrHPV testing on self-collected samples is a safe alternative 
for cytology testing on physician-taken samples. 
Despite some variations between studies, also sufficient evidence has been 
collected that highly concordant results can be obtained between hrHPV testing on self- 
and physician-sampled specimens at the level of CIN2+ detection.(18;23;25;29) This is 
supported by data from the non-attendees of our PROHTECT-1 study.(17) Relative to their 
(hrHPV plus cytology triage) screened counterparts of the same age category in the 
regular screening programme, non-responder women of < 33 years demonstrated a 
similar CIN2+ rate (i.e. 0.8%; RR 0.81; 95% CI 0.53 – 1.21). Since women of this age 
had no previous screening round, this strongly suggests that the sensitivity for CIN2+ of 
hrHPV testing on self-samples is not inferior to that of hrHPV testing on physician-
collected cervical samples. Variations in reported study results likely reflect the use of 
different collection devices and HPV tests and protocols Therefore, for reaching clinical 
equivalence in terms of detecting CIN2+ the right combination of self-sampler and 
validated hrHPV test is likely to be important.  
Given abovementioned properties, it can be envisioned that hrHPV-testing on 
self-sampled specimens may have value as an alternative screening tool in regular, 
population-based screening and/or monitoring of women treated for CIN2+. Therefore, 
the time has come for an implementation study in which HPV testing on self-sampled 
cervico-vaginal material is offered as an alternative for HPV testing on a physician taken 
smear for CIN2+ detection in the regular screening programme. Also the Dutch Health 
Council has recently advised to perform such a study. 
In addition, substantial improvements in the context of triage testing can be 
foreseen. Since cytomorphology on self-sampled specimens is not an option, women 
who tested hrHPV-positive on their self-sample are currently advised to visit a physician 
for a cervical smear. Application of molecular triage testing (i.e., testing for the presence 
of CIN2+ disease-related markers by molecular analysis) directly on the self-sampled 
specimens is nowadays a feasible option. A recent study presents an objective 
methylation marker panel (i.e., CADM1 and MAL) that was equally discriminatory for 
CIN3+ as cytology or cytology with HPV16/18 genotyping on physician-taken cervical 
smears in hrHPV-positive women.(34) The efficacy of this molecular triage strategy on 
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self-samples is currently being evaluated against that of triage via the general 
practitioner in the PROHTECT-3 trial. Molecular triage on self-samples opens the 
possibility for complete women-friendly cervical screening using objective, non-
morphological molecular methods. 
 
 
Figure 1a: the self-sampling lavage device (Delphi®-Screener), used in PROHTECT-1 
 
 
 
 
 
 
Figure 1b: Updated version of the Delphi® screener presently in use 
 
 
 
 
 
 
 
Figure 2: the self-sampling brush device (Viba-Brush®) 
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8.1 Baarmoederhalskanker en voorloperstadia 
Baarmoederhalskanker is wereldwijd één van de meest voorkomende vormen 
van kanker bij vrouwen. Baarmoederhalskanker komt voor bij vrouwen van alle 
leeftijden, maar het meest bij vrouwen in de leeftijd van 35 tot 50 jaar. Elk jaar krijgen in 
Nederland ongeveer 630 vrouwen baarmoederhalskanker, en jaarlijks overlijden 
ongeveer 230 vrouwen aan deze ziekte. Een infectie met het humaan papillomavirus 
(HPV) is noodzakelijk voor het ontstaan van baarmoederhalskanker.  
Baarmoederhalskanker kan ontstaan wanneer het evenwicht tussen de opbouw 
en de afbraak van het slijmvlies van de baarmoedermond verstoord is. Meestal worden 
deze afwijkingen veroorzaakt door een ontsteking of infectie, bijvoorbeeld met HPV. Bij 
zo‘n ontregeling kunnen afwijkingen van de baarmoedermond, zogenaamde laesies, 
ontstaan. Deze afwijkingen verdwijnen vaak vanzelf door optreden van het 
afweersysteem (immuunsysteem) van de vrouw. Mocht het immuunsysteem de oorzaak 
van deze laesies zoals de HPV infectie niet kunnen onderdrukken, dan kunnen steeds 
meer afwijkende cellen ontstaan. Men spreekt dan van een voorstadium van 
baarmoederhalskanker. Deze voorstadia worden CIN (= cervicale intraepitheliale 
neoplasie) graad 1 (CIN1), - graad 2 (CIN2) en - graad 3 (CIN3) genoemd. Zonder 
behandeling kunnen deze CIN laesies zich uiteindelijk ontwikkelen tot 
baarmoederhalskanker. Het proces van het ontwikkelen van een voorstadium tot 
baarmoederhalskanker verloopt heel langzaam en kan wel tien tot vijftien jaar duren. 
 
8.2 Humaan papillomavirus (HPV) 
Baarmoederhalskanker wordt veroorzaakt door een voortdurende (persistente) 
infectie met een kankerverwekkend, zogenaamd hoog-risico, type van HPV. Deze 
ontdekking heeft geresulteerd in nieuwe mogelijkheden voor preventie van 
baarmoederhalskanker, namelijk profylactische HPV vaccins en het gebruik van de HPV 
test (d.w.z. een test die de aan- of afwezigheid van het virus meet) binnen het 
bevolkingsonderzoek naar baarmoederhalskanker (BVO BMHK). 
HPV infecties komen veel voor en er zijn meer dan honderd verschillende types 
van het virus bekend. Van een deel van deze types, ongeveer 15, is bekend dat zij 
baarmoederhalskanker kunnen veroorzaken. Deze type virussen worden dan ook 
oncogene (kankerverwekkende) typen, of hoog risico HPV (hrHPV) typen genoemd.  
HPV infectie van de baarmoedermond kan ontstaan door 
geslachtsgemeenschap. Een infectie van de baarmoedermond met HPV komt 
gedurende het leven voor bij 80% van alle vrouwen. Bij de meerderheid, ~90%, van de 
geïnfecteerde vrouwen is het lichaam in staat het virus te klaren met haar eigen 
immuunsysteem. Wanneer het immuunsysteem niet in staat is de virusinfectie op te 
ruimen, blijft het virus in het slijmvlies van de baarmoedermond zitten en kunnen de 
bovengenoemde voorstadia (CIN laesies) onstaan. Bij de lichte vorm van deze 
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voorstadia zoals CIN1 kan de infectie, en daarmee de laesie, nog in 95% van de 
gevallen genezen. Bij CIN2 en CIN3 wordt de kans op volledig herstel steeds kleiner. 
Een klein deel van alle vrouwen waarin de infectie niet geneest, kan na verloop van 10 
of meer jaar baarmoederhalskanker ontwikkelen hetgeen gepaard gaat met 
veranderingen in het genoom (ofwel het kernmateriaal) van de geïnfecteerde cel. Deze 
veranderingen zorgen voor de functionele veranderingen van de hrHPV-geïnfecteerde 
cel, waardoor deze ongecontroleerd kan gaan groeien.  
 
8.3 Het bevolkingsonderzoek naar baarmoederhalskanker (BVO BMHK) 
De lange periode van voorstadia bij het ontstaan van baarmoederhalskanker 
biedt de mogelijkheid voor het vroeg detecteren van deze ziekte. Vroege detectie maakt 
betere behandeling mogelijk en verhoogt de kans op genezing, en kan daarmee het 
ontstaan van baarmoederhalskanker voorkomen. Het bevolkingsonderzoek naar 
baarmoederhalskanker (BVO BMHK) is al in de jaren ‘70 van de vorige eeuw 
geïntroduceerd, met als doel het opsporen van voorloopstadia en het aantal gevallen 
van baarmoederhalskanker te reduceren. In 1989 was er min of meer landelijke dekking 
van het BVO BMHK. Niettemin, in 1996 was grondige herziening van de organisatie van 
het BVO BMHK nodig, om meer vrouwen deel te laten nemen en om het aantal 
opportunistische uitstrijkjes terug te dringen. Ook het aantal herhalingsuitstrijkjes werd 
teruggedrongen door nieuwe classificatie (beoordeling van de uitstrijkjes) in te voeren. 
Sindsdien worden in Nederland vrouwen tussen de 30 en 60 jaar om de 5 jaar voor het 
BVO BMHK opgeroepen om een uitstrijkje te laten maken bij de huisarts. Bij het 
detecteren van abnormale cellen in dit uitstrijkje wordt de patiënte doorverwezen naar de 
gynaecoloog. De periode sinds 1996 tot heden is eigenlijk nog te kort om daadwerkelijk 
effecten te kunnen meten van de invoor van de veranderingen. Toch is er sinds 1989 
wel een vermindering van de incidentie van baarmoederhalskanker opgetreden van 9,1 
per 100.000 vrouwen in 1989 tot 7,9 per 100.000 vrouwen in 2007. Dit is een 
vermindering van circa 13%. 
 
8.4 Niet-deelneemsters binnen het BVO BMHK 
Ondanks de landelijk invoering van BVO BMHK in 1989 is de dekkingsgraad (= 
het percentage vrouwen met een baarmoeder/baarmoedermong dat een uitstrijkje laat 
maken) niet volledig. Slechts 77% van alle vrouwen hebben, gemeten over één ronde 
van het BVO BMHK, een uitstrijkje laten maken. Drie-en-twintig procent van de vrouwen 
laat (bijna) nooit in hun leven een uitstrijkje maken (zogenaamde niet-deelneemsters).  
 In hoofdstuk 2 hebben we aangetoond dat 55% van de gevallen van 
baarmoederhalskanker gediagnosticeerd wordt onder niet-deelneemsters. Klaarblijkelijk 
hebben niet-deelneemster een hoger risico op het ontwikkelen van baarmoederkanker 
dan vrouwen die wel deelnemen aan het BVO BMHK. Omdat niet-deelneemsters zich 
niet laten controleren worden mogelijke voorloopstadia gemist, met als gevolg dat de 
voorloopstadia zich verder kunnen ontwikkelen tot baarmoederhalskanker.  
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Het is lastig te onderzoeken wat de motieven zijn van vrouwen om niet deel te 
nemen aan het BVO BMHK, maar verschillende onderzoekingen wijzen op een rol van 
de volgende factoren: geen vertrouwen in de huisarts/medische wereld, geen tijd 
(werkende vrouwen), vanwege religieuze redenen / cultuur, misvatting omtrent het risico 
op baarmoederhalskanker, en gevoelens van schaamte en/of angst voor de ingreep 
(pijn, ongemak) bij de huisarts.  
 
8.5 De thuistest als oplossing voor niet-deelneemsters 
Om de vrouwen die niet willen of kunnen deelnemen aan het BVO BMHK een 
alternatief te bieden, hebben we in 2006 het PROHTECT thuistestonderzoek opgezet. 
Dit onderzoek was bedoeld voor vrouwen die in 2005 of 2006 uitgenodigd waren voor 
het BVO BMHK maar niet deelgenomen hadden. Hen werd alsnog een mogelijk 
geboden om deel te nemen. Deze vrouwen waren woonachtig in de regio Noord-Holland 
of Flevoland. De vrouwen hadden niet gereageerd op hun oproep voor een uitstrijk 
alsmede niet op een herhaaloproep. Deze niet-deelneemsters kregen tussen eind 2006 
en medio 2008 een thuistest opgestuurd om zodoende zelf, thuis slijmvlies van de 
baarmoedermond te kunnen afnemen voor nader onderzoek in het laboratorium. Na 
zenden van het zelf-afgenomen materiaal naar het laboratorium (VU medisch centrum 
Amsterdam) werden de zelf-afgenomen materialen onderzocht met behulp van de HPV 
test. Indien hrHPV aangetoond werd in het zelf-afgenomen materiaal, dan kregen de 
vrouwen het advies om naar de huisarts te gaan voor het laten maken van een uitstrijkje. 
Wanneer vervolgens abnormale cellen werden gevonden in het uitstrijkje, werden de 
vrouwen naar de gynaecoloog doorverwezen. 
Het doel van het onderzoek was om na te gaan of niet-deelneemsters wel op de 
thuistest zouden reageren en bereid zouden zijn om, indien zij hrHPV positief getest 
zouden zijn, zich verder te laten onderzoeken door een huisarts/gynaecoloog. Tevens 
wilden we analyseren of de thuistest met HPV test geschikt was om CIN laesies te 
kunnen detecteren.  
Het onderzoek wees uit dat het aanbieden van de thuistest aan niet-
deelneemsters een goede manier is om niet-deelneemsters alsnog te laten deelnemen 
aan het BVO BMHK, want 30% van deze vrouwen deed mee aan het 
thuistestonderzoek. Dit zou betekenen dat bij het landelijk invoeren van de thuistest aan 
niet-deelneemsters, de dekkingsgraad van het BVO BMHK met zo‘n 7% (=30% van 
23%) zou kunnen toenemen. Wij kunnen hieruit concluderen dat de thuistestmethode 
voor een deel van de vrouwen de factor tot niet-deelname aan het BVO BMHK 
wegneemt. 
Van de 30% van de vrouwen die deelnam aan de thuisteststudie, bleek 9,3% 
geïnfecteerd te zijn met hrHPV. Ongeveer 90% van deze vrouwen zijn naar de huisarts 
geweest voor het laten maken van een uitstrijkje. Iets meer dan een kwart van deze 
vrouwen hadden een afwijkend uitstrijkje en werden geadviseerd om naar de 
gynaecoloog te gaan voor verder onderzoek. Ongeveer 94% van deze vrouwen gaf 
hieraan gehoor. In totaal hadden 61 vrouwen CIN2 (matige dysplasie), 144 vrouwen 
CIN3 (ernstige dysplasie), en 13 vrouwen baarmoederhalskanker. Als we deze getallen 
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afzetten tegen de getallen onder vrouwen die regulier deelnemen aan het BVO BMHK, 
dan zien we dat niet-deelneemsters significant meer afwijkingen hebben dan vrouwen 
die recent een uitstrijkje hebben laten maken. M.a.w. de groep niet-deelneemsters kent 
inderdaad een verhoogd risico voor het ontwikkelen van baarmoederhalskanker.  
De thuistest is in twee fasen uitgevoerd, met als belangrijkste verschil tussen de 
twee onderzoeken het type thuistest en de geboortejaren. Het eerste onderzoek betrof 
een thuistest welke een spoeling van de baarmoedermond uitvoerde om cellen van de 
baarmoedermond en vagina te verzamelen (hoofdstuk 3). Het tweede onderzoek 
maakte gebruik van een borsteltje om cellen van de baarmoedermond/vagina te 
verzamelen (hoofdstuk 4). Het tweede onderzoek is uitgevoerd onder vrouwen welke 1 
jaar later waren uitgenodigd voor het laten maken van een uitstrijkje dan de vrouwen uit 
het eerste onderzoek. Het betrof derhalve een opschuiving van 1 jaar in geboortejaren. 
Vergelijking van de gegevens van beide fasen van het onderzoek toonden dat het type 
thuistest geen verschil maakt voor het uiteindelijke resultaat van het aanbieden van een 
thuistest; de vrouwen in beide onderzoeken waren even bereid (zo‘n 30%) om deel te 
nemen aan het thuistest onderzoek. Tevens werd een gelijke hoeveelheid CIN laesies 
gevonden in beide fasen van het onderzoek.  
Door het samenvoegen van de onderzoeksgegevens van de twee fasen van het 
onderzoek werden aanvullende analysen mogelijk, namelijk of etniciteit, uitstrijk-
voorgeschiedenis en leeftijd van de vrouw invloed hebben op wel/niet deelname aan een 
thuistestonderzoek en de kans op het hebben van CIN laesies (hoofdstuk 5). Het 
analyseren van de gecombineerde onderzoeksgegevens per etniciteit toonde dat in 
Nederland wonende ―Westerse‖ vrouwen (Europa, Australië, Nieuw-Zeeland, Canada en 
VS) significant meer meedoen aan het thuistestonderzoek dan in Nederland wonende 
―niet-Westerse‖ vrouwen (Azië, Afrika, Midden-Oosten, Midden- en Zuid-Amerika). 
Verder hadden ook de leeftijd en hun uitstrijk-voorgeschiedenis invloed op de 
deelnamebeslissing; jongere vrouwen deden meer mee dan oudere vrouwen en het 
deelnamepercentage onder vrouwen die nog nooit hadden deelgenomen aan het BVO 
BMHK was hoger dan onder vrouwen die weleens eerder een uitstrijkje hadden laten 
maken binnen het BVO BMHK. M.a.w. een belangrijke groep vrouwen die nooit een 
uitstrijkje hebben laten maken, wordt bereikt met de thuistest methode. Deze 
bevindingen waren gelijk voor beide fasen van de studie. De kans op laesies werd alleen 
beïnvloed door hun beslissing om wel/niet deel te nemen aan het BVO en niet door 
etniciteit of leeftijd. 
In hoofdstuk 6 analyseerden we de vrouwen die behandeld waren voor hun 
hooggradig CIN laesie. We keken of er een relatie was tussen de verschillende hrHPV 
typen en de kans op het herkrijgen van de laesie. Hieruit bleek dat vrouwen die 
geïnfecteerd waren met hrHPV type 16, het meest voorkomende HPV type, de grootste 
kans hadden op wederom een CIN laesie binnen een paar jaar. Hieruit kunnen we 
concluderen dat de gynaecologen extra aandacht dienen te geven aan deze groep 
vrouwen. 
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8.6 Conclusie 
Wij hebben laten zien dat de thuistest methode geschikt is om niet-
deelneemsters van het BVO BMHK te kunnen bereiken. PROHTECT thuistestonderzoek 
laat zien dat het aanbieden van een thuistest met een hrHPV test in het laboratorium, 
een uitvoerbare en efficiënte benadering is die de effectiviteit van het 
bevolkingsonderzoek naar baarmoederhalskanker kan verbeteren. Ons onderzoek heeft 
dit met name getest onder de groep vrouwen die niet hadden gereageerd op een 
uitnodiging voor het laten maken van een uitstrijkje binnen het BVO BMHK. Ruim 30% 
van de niet-deelneemsters bleek wel deel te willen nemen aan het BVO BMHK wanneer 
hen de mogelijkheid van een thuistest werd geboden. In deze groep niet-deelneemsters 
vonden we uiteindelijk een hoger dan normaal percentage voorloperstadia alsmede 13 
gevallen van baarmoederhalskanker. We concluderen dat de thuistestmethode en het 
daarbij behorend protocol geschikt is om hooggradige voorloperstadia te detecteren en 
daarmee baarmoederhalskanker te voorkomen, juist in de groep vrouwen die 
onvoldoende deelneemt aan het BVO BMHK. 
In de toekomst zou deze thuistestmethode uitermate geschikt zijn om breed te 
implementeren in het BVO BMHK. Niet alleen niet-deelneemsters, maar alle vrouwen 
die dit wensen zouden dan in aanmerking moeten kunnen komen voor de thuistest. 
Hiermee kan de dekkingsgraad toenemen, het aantal gevallen van CIN laesies afnemen 
en de kwaliteit van het BVO BMHK verbeteren. Verder kan dit de werkdruk van de 
huisarts doen afnemen, omdat alleen de HPV-positieve vrouwen zullen worden 
geadviseerd om naar de huisarts te gaan. Recente onderzoeken hebben laten zien dat 
de HPV test in combinatie met een thuistest een even betrouwbaarder resultaat (dwz 
detectie van baarmoederhalskanker en de ernstige voorloperstadia daarvan) geeft als 
het klassieke uitstrijkje of het uitstrijkje met een HPV test. Deze resultaten 
rechtvaardigen om in de toekomst ook de HPV thuistest als onderdeel van het BVO 
BMHK in Nederland te implementeren.  
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